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ABSTRACT 
 
A major challenge associated with delivery of active agents in the female reproductive 
tract (FRT) is the ability of agents to efficiently diffuse through the cervicovaginal mucosa 
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(CVM) and reach the underlying sub-epithelial immune cell layer and vasculature. A variety of 
drug delivery vehicles have been employed to improve the delivery of agents across the CVM 
and offer the capability to increase the longevity and retention of active agents to treat infections 
of the female reproductive tract. Nanoparticles (NPs) have been shown to improve retention, 
diffusion, and cell-specific targeting via specific surface modifications, relative to other delivery 
platforms. In particular, polymeric NPs represent a promising option that has shown improved 
distribution through the CVM. This work summarizes recent experimental studies that have 
evaluated NP transport in the FRT, and highlights research areas that more thoroughly and 
efficiently inform polymeric NP design, including mathematical modeling. 
The studies presented below further expand on this to investigate the application of NPs 
in treating cancers found within the FRT. Advanced stage cancer treatments are often invasive 
and painful—typically comprised of surgery, chemotherapy, and/or radiation treatment. In 
addition to the poor transport associated with intravaginal delivery, low transport efficiency 
during systemic chemotherapy may require high chemotherapeutic doses to effectively target 
cancerous tissue, resulting in systemic toxicity. Nanotherapeutic platforms have been proposed 
as an alternative to more safely and effectively deliver therapeutic agents directly to tumor sites. 
However, cellular internalization and tumor penetration are often diametrically opposed, with 
limited access to tumor regions distal from vasculature, due to irregular tissue morphologies. To 
address these transport challenges, NPs are often surface-modified with ligands to enhance 
transport and longevity after localized or systemic administration. In the work presented below, 
the effect of surface modification with stealth polyethylene–glycol (PEG), cell-penetrating 
(MPG), and CPP-stealth (MPG/PEG) poly(lactic-co-glycolic-acid) (PLGA) NP co-treatment 
strategies on NP distribution and chemotherapeutic efficacy, which is defined in this work as the  
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ability of NPs to impart drug cytotoxicity and potency, was evaluated with the use of 3D cell 
culture models representing hypo-vascularized cervical cancerous tissue. 
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Evaluation of Experimental Systems and the Potential for Mathematical Modeling 
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Female Reproductive Tract: Evaluation of Experimental Systems and the  
Potential for Mathematical Modeling; 2018; Accepted 
 
A. CURRENT CHALLENGES TO CONVENTIONAL DRUG DELIVERY  
Mucosal tissue is a critical barrier that defends the body from pathogen infection, typically lining 
the surface of internal organs and body cavities. Within the female reproductive tract (FRT), the 
vaginal mucosa is comprised of three layers that possess unique characteristics relevant to their 
protective functions (Figure 1).3,4  The secreted mucus layer, located on the apical side of the 
mucosa, is comprised of polymerized mucin fibers and 
globular secretions. Cervical mucus is produced by the 
ectocervix and forms cervicovaginal mucus (CVM) 
that locally lines the cervix, as well as the vaginal 
compartment. Beneath the mucus, within the vaginal 
compartment, lies the stratified epithelium, which is 
approximately 200-400 μm thick. The lamina propria 
(or stroma) lies at the basal portion of the mucosa and is the thickest (2.5-3 mm) and most 
complex of the three layers. Similar to the apical mucus, an array of mucin fibers can also be 
found within the stroma.5 The arrangement of these mucin fibers, in parallel fiber networks or 
more randomized patterns, is influenced by menstrual and ovulation cycles. In addition, the 
stroma contains immune (e.g., CD3+ and CD4+ T lymphocytes) and host (e.g., macrophage, 
fibroblast) cells that are recruited to mediate the host-antimicrobial response.  
The physiological and anatomical complexity of the FRT maintains the health of the microbiota 
and host cells by acting as a first line of defense against incoming pathogens. Yet the 
Figure I. Schematic cross-section of the FRT. 
Mucus (top), epithelium (middle) and stromal 
layer containing immune cells and fibroblasts 
(bottom). 
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effectiveness of the CVM as a barrier to infection can present significant challenges to the 
localized administration of microbicidal, antiviral, and antibiotic agents. Traditional dosage 
forms and delivery vehicles that deliver prophylactic and therapeutic active agents to the FRT, 
such as intravaginal rings, gels, and films face numerous obstacles including: rapid clearance and 
dilution of topically applied active agents due to vaginal fluids, minimal diffusion through the 
CVM, poor transport to underlying tissue, and inadequate, heterogeneous agent distribution. To 
address these challenges, a variety of platforms have been developed to deliver therapeutic 
agents across the CVM, while also increasing the longevity and retention of active agents in the 
FRT. These platforms offer numerous advantages over traditional dosage forms by protecting 
active agents from degradation in the harsh acidic vaginal microenvironment, providing 
sustained-release to improve the longevity and efficacy of the therapeutic payload, as well as 
enabling the high encapsulation and localized delivery of hydrophobic and hydrophilic agents 
(Table 1). For a more thorough review of microbicide delivery platforms please refer to  6-11. 
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Table 1.  Overview of microbicide delivery vehicles currently used or investigated 
for delivery  to the FRT. 
 
A promising platform that has been utilized to improve distribution through the CVM is based on 
polymeric nanoparticles (NPs).1,2,7-9,11-37 Due to small sizes, often ranging from 70 to 300 nm, 
NPs exhibit unique physical properties that 
make them advantageous for delivery to the 
FRT, often providing desirable diffusion and 
transport kinetics through the CVM. By 
incorporating different surface modifications, 
NPs can improve retention, diffusion, and cell-
specific targeting, relative to other delivery 
platforms. Additionally, polymeric NPs are 
typically made from non-toxic, non-
inflammatory, FDA-approved polymers, which 
Figure 2. (A) Schematic of unmodified (blue only) 
and surface-modified mucoadhesive (yellow) and 
muco-inert (green) NPs. (B) Representative 
distribution of mucoadhesive and muco-inert NPs in 
the vaginal mucosa.  
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improve biocompatibility – a factor of significant importance due to the propensity for vaginal 
infections. The nanoscale properties, including high surface area to volume ratio, can impart 
favorable tunability in transport properties. This is achieved through NP surface modifications, 
by utilizing different surface chemistries to conjugate or adsorb ligands to the NP surface. These 
modifications can either enhance NP diffusion through the CVM via muco-inert properties, or 
can impart mucoadhesive characteristics for greater longevity in the basal mucus layer (Figure 
2).7,20,21,25,31,32,36,38-40 Hence, NPs can directly carry therapeutic payloads and navigate through 
the porous CVM, increasing agent penetration and transport. Moreover, alterations in 
physicochemical properties can be adapted to attain desired pharmacokinetic (PK) and 
pharmacodynamic (PD) properties.1,2,8,9,12,16,17,21,25,36,39,41  Thus, polymeric NPs can be designed 
to overcome transport barriers and to deliver effective doses to target sites, while maintaining 
agent activity and minimizing adverse effects on surrounding tissue.  
 
To more effectively design delivery vehicles for application to the FRT, an in-depth 
understanding is needed of the anatomical and physiological structure of the vaginal 
microenvironment and how these structural characteristics may directly or indirectly affect NP 
diffusion and transport. A variety of studies have examined the impact of mucin fibers, found in 
the apical and basal layers of the mucosa, on NP distribution and transport.14,42  Mucin, a major 
structural component of mucus, is a high molecular weight, anionic molecule that non-covalently 
interacts to create a mesh-like framework.  Depending on the arrangement, size, and porosity of 
these mucin fibers, active agent and delivery vehicle penetration are impeded, similar to virus 
penetration.43-45 Additionally, the affinity for NPs to reversibly bind to mucin fibers has been 
studied and shown to impact NP diffusion. These studies, discussed in more detail below, 
provide insight into the dependence of diffusion through the mucosa on ligand choice, surface 
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modification density, and ligand molecular weight. Although NP diffusion and transport, as a 
function of these alterations, have been experimentally studied in vitro and in vivo, limitless 
alterations exist, making it difficult to iteratively test all of the parameters that can impact 
binding, diffusion, and internalization.  
 
In parallel with experimental design, mathematical modeling has been used to validate and 
predict factors that play pivotal roles in drug and NP distribution, particularly in the field of 
cancer. Mathematical models have been used to obtain more detailed insights into how specific 
parameters including size, shape, surface modifications, and drug loading affect NP diffusion, 
without having to perform exhaustive experiments to inform design.46-68  
 
The goal of this chapter is to highlight recent experimental studies that have evaluated NP 
transport in the FRT. As there have been to our knowledge no mathematical studies evaluating 
NP transport in the FRT, we focus on modeling studies that have evaluated small molecule 
transport, and describe research parameters and regimens that may be expanded upon to more 
thoroughly and efficiently inform potential NP design. We first present an overview of the in 
vitro, ex vivo, and in vivo polymeric NP studies conducted to date, by which transport parameters 
are determined, extrapolated, and validated. Secondly, we summarize how different NP design 
features have impacted FRT transport, and identify gaps that exist due to the limitations of 
iterative experimentation alone. We then discuss the potential of mathematical modeling as a 
complementary means to characterize and evaluate diffusion and transport of delivery vehicles 
and active agents through the CVM. Lastly, we suggest potential advancements combining 
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mathematical and experimental knowledge to inform next-generation designs, such that optimal 
NP binding, diffusion, and internalization in the FRT may be achieved. 
B. INFORMING NANOPARTICLE DESIGN WITH EMPIRICAL STUDIES 
i. Introduction to factors that guide experimental studies 
As the field of intravaginal drug delivery has evolved, a variety of experimental methods have 
been established to study molecular and NP transport in vaginal mucosa models. In vitro, ex vivo, 
and in vivo methods have provided insight into the pharmacologic behaviors of molecules and 
delivery vehicles, particularly their movement through the CVM. Each type of experimental 
model provides information regarding transport and the interactions that modulate this transport, 
with varying degrees of physiological complexity and accuracy.  
 
The most controlled methods to study molecular diffusion and transport are provided by in vitro 
experimental models, in which individual cell uptake and effect can be evaluated. However, 
monolayer cell culture often fails to adequately represent a system in which NPs undergo 
diffusive flux as they would in vivo, due to the inability of these systems to accurately represent 
3D physiologic architecture and microenvironmental conditions. To more faithfully represent the 
mucosal environment, more advanced in vitro systems such as synthetic mucus,69 undiluted 
CVM collected from human patients,13,22,30,31,35,70-72 and 3D cell culture techniques have been 
developed.1,28,52,55,73-77   
 
In addition to utilizing a relevant model to study and obtain transport information, essential 
physical and chemical properties must be considered to effectively design NPs to navigate the 
CVM. Depending on whether mucoadhesive or muco-inert properties are preferred, these 
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properties may be tailored to enhance distribution through mucus and to the underlying epithelial 
and stromal cell layers. A particular physical parameter, NP size, has been found to impact NP 
diffusion and transport kinetics, due to the pore size of the surrounding CVM.3,22,23,42 If NPs are 
larger than the average CVM pore diameter, effective transport may be hindered by physical and 
chemical interactions with mucin fibers. Contributing to these interactions, NP surface chemistry 
also impacts NP transport: surface charge, colloidal stability, surface-modifying agent of choice, 
molecular weight, and ligand surface density all affect NP interactions with the mucosa.13,20-
22,26,27,30,31,34,35,37,40,43,72,78 These factors can influence how NPs, in a concentration-dependent 
manner, interact with one another.  
 
Together, these factors contribute to the complexities associated with first understanding NP 
diffusion within the CVM, and subsequently designing optimal NP delivery vehicles to meet the 
needs of a given application or physiological environment. Previous literature reviews 7-
9,11,17,19,27,32,38 have focused on the therapeutic efficacy of NP delivery systems and their potential 
applications in the FRT environment. Here, we highlight different in vitro, ex vivo, and in vivo 
techniques that have been implemented to better understand how the relevant parameters 
influence NP diffusion and transport kinetics in the CVM. In this section we present these 
techniques and summarize how they have been utilized to gain deeper insights into the 
complexities of NP delivery within the FRT.  
   
ii. In vitro transport studies 
a. HUMAN CVM STUDIES 
Transport dependence on NP size and surface modifications 
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Within the field of intravaginal drug delivery, CVM samples are often collected from patients 
and serve as important specimens to study NP transport and diffusion. This methodology 
provides a near perfect physiological mucus model in which NP transport may be 
studied.4,14,20,22,23,30,31,35,70,71 In a seminal study by Saltzman and group, fresh, mid-cycle cervical 
mucus was obtained from healthy human patients and used to investigate how mucus properties 
change based on interactions with synthetic polymers.72 In the study, the addition of nonionic or 
cationic polymers such as polyethylene glycol (PEG) or polyvinylpyrrolidone (PVP) altered the 
gel-like structure of mucus. It was discovered that the addition of PEG (3350 Da) affected the 
structural properties of mucus by inducing hydrogen bond formation, leading to mucin fiber 
coalescence in regions  that were in contact with the polymer, thereby creating larger pore sizes. 
In contrast, the addition of anionic polymers like poly(lactic-co-glycolic) acid (PLGA), had no 
effect on the mucus properties.72 The inability of PLGA to induce structural changes within 
CVM may correlate with the observation that PLGA NPs tend to immobilize within the CVM, 
while, conversely, the ability of PEG to alter mucin fiber arrangement may contribute to the 
enhanced diffusivity of PEG-modified NPs, as discussed in greater detail below. The results 
from this pioneering study highlight the impact of polymer selection on NP-CVM interactions.72 
 
In later work, human CVM was used in vitro to investigate the diffusion kinetics of different 
polymeric NP formulations, including polystyrene (PS) and PLGA NPs.22,23,29-31,34,35,37,79 In these 
studies, undiluted CVM secretions were collected from women who displayed a healthy vaginal 
flora,. Utilizing these specimens, Hanes and group investigated the relative diffusivities of 
different NP formulations.22,23,29-31,34,35,37,79 Parameters that were of particular interest were NP 
size and the molecular weight and surface density of NP modifications, such as PEG. In one such 
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study investigating the physical properties of NP size and surface charge, it was found that PS 
NPs, with diameters spanning 200-500 nm, exhibited more rapid diffusion independent of 
surface chemistry and charge, relative to smaller, 100 nm NPs.22 This was contrary to the 
hypothesis that NPs with a diameter larger than the CVM pore size would have lower diffusion 
coefficients, relative to NPs with diameters smaller than the average pore size. Polystyrene NPs 
modified with PEG (PEGylated, 2 kDa) ranging in size from 100, 200, and 500 nm exhibited 20-
, 400-, and 1,100-fold higher average mean squared displacements (MSDs) relative to 
unmodified carboxylated (PS-COOH) NPs of the same size. Furthermore, NPs with larger 
diameters and dense PEG coatings diffused through the CVM more rapidly, with diffusion 
coefficients reduced by 2,000-, 6-, and 4-fold for 100, 200, and 500 nm PEGylated NPs, relative 
to diffusion in water. In contrast, it was observed that PS-COOH NPs (without modification) 
were unable to diffuse through the CVM and were strongly mucoadhesive.22  This phenomenon 
was attributed to the addition of PEG, preventing polyvalent bond formation between PS NPs 
and hydrophobic mucin fiber domains. From this study it was found that NP surface chemistry 
plays a vital role in diffusion through CVM. 
 
To further explore the impact of NP size on CVM diffusion, a separate study investigated how 
the nanoscale mucus rheology changes upon exposure to differently sized non-mucoadhesive 
beads.70 In fresh, undiluted human CVM, the mucosa acted as an impermeable elastic barrier to 
non-mucoadhesive beads with diameters equal to or greater than 1 m, while the CVM 
resembled a highly permeable viscoelastic liquid for beads with a diameter less than or equal to 
500 nm. However, after addition of a nonionic detergent, the CVM transitioned to an 
impermeable elastic barrier, even for the small beads.70 This change in mucus viscoelasticity is in 
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accordance with the results from 22, suggesting that NPs with diameters spanning 200 to 500 nm, 
achieve maximum diffusion.  
 
To gain further insight regarding the role of mucin fiber pore size in NP diffusion and to expand 
on the study by 22, experiments were conducted to investigate the effect of size on NP 
penetration through the CVM.23 Polystyrene NPs were modified with a high density, low 
molecular weight, amine-modified PEG (2.0-3.4 kDa) to deter mucus adhesion. When observed 
in undiluted human CVM, PEG-modified PS NPs with sizes 100, 200, and 500 nm effectively 
penetrated mucus and exhibited diffusivities 6.5-, 3.5-, and 12-fold lower than that of NPs in 
water, respectively. However, PEG-modified PS NPs with a diameter of 1 μm diffused 200-fold 
more slowly in mucus than in water. Using this information, the diffusion rates were fit to a 
previously derived obstruction-scaling model for cross-linked gels to determine the pore size of 
CVM.23,80 While the pore size of undiluted human CVM was found to be 340 ± 70 nm, this wide 
distribution highlights the additional complexities of transport in the CVM. Additionally, the 
large difference in diffusion coefficients between the 0.5 and 1 μm PS NPs emphasizes the 
importance of NP diameter in NP design. 
 
In addition to NP size, ligand density and surface modification type play critical roles in the 
transport of NPs in human CVM. The effect of PEG as a surface-modification for PLGA NPs 
and its impact on CVM binding and diffusion were investigated as a function of PEG molecular 
weight (2, 5, and 10 kDa) and modification density (5-100%).14 As predicted by the 
investigators, the addition of PEG to the NP surface impacted the physical properties of the NPs 
by improving colloidal stability and neutralizing the NP surface charge. PEGylated NPs were 
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also observed to have higher diffusion coefficients in human cervical mucus. Additionally, NPs 
partially-modified with PEG (10%) had a higher dependency on PEG molecular weight, whereas 
NPs partially-modified (10%) with 10 kDa PEG exhibited no difference relative to fully-
modified PEGylated NPs using 2 and 5 kDa PEG.14 Based on PEG molecular weight, the 
partially-modified PEGylated NP formulations (10%) with 5 or 10 kDa PEG demonstrated 
statistically improved CVM diffusion relative to unmodified and 2 kDa partially-modified PLGA 
NPs. These results highlight the interdependency of PEG molecular weight and modification 
density on NP diffusion through CVM.  
 
 
Transport dependence on NP formulation chemistry and synthesis 
As high PEG-modification density was observed to promote mucus penetration and decrease NP 
immobilization, similar studies sought to identify ways to maximize ligand conjugation to the NP 
surface.30,37  One of the challenges in obtaining high degrees of post-synthesis surface 
modification is that with conventional polymers, such as PS and PLGA, there are a limited 
number of surface groups available for conjugation, thereby limiting the density at which PEG 
(and other ligands) can be conjugated to the NP surface. To overcome this obstacle, PEG was 
covalently conjugated to the backbone of poly(sebacic acid) (PSA) to create a diblock copolymer 
that resulted in muco-inert NPs.30 The trajectories and diffusion coefficients of PSA-PEG, 
relative to unmodified PSA and PLGA NPs were observed in undiluted human CVM. PSA-PEG 
NPs were significantly more mobile in CVM, having a MSD 400- and 230-fold higher than PSA 
and PLGA NPs, respectively, confirming the correlation between high PEG density and rapid NP 
diffusion and transport through the CVM.  
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Another study investigated the use of biodegradable polymers to formulate diblock copolymers 
of PLGA (18 kDa; L/G=50:50) and PEG (2 kDa) to promote mucus-penetrating NP properties.37 
The chemical structure of the diblock polymer, confirmed via H-NMR and NP characterization 
with dynamic light scattering, revealed that PLGA and PLGA-PEG NPs possessed average 
hydrodynamic diameters of 130 and 90 nm, respectively. To assess NP diffusion, fresh undiluted 
CVM was collected from human patients and in this system, PLGA-PEG NPs were observed to 
diffuse much faster than PLGA NPs alone, with diffusion coefficients 8,000 and 12,000-fold 
lower than in water, respectively. Based on these results, it was suggested that ~75% of PLGA-
PEG NPs would penetrate a 10 µm thick mucus layer in 30 min, whereas PLGA NPs would 
exhibit negligible penetration within this duration.37 Due to the rapid clearance of the CVM ‒ on 
the order of minutes to hours ‒ it is highly desirable that topically administered NPs penetrate 
and diffuse into tissue prior to mucosal clearance. Furthermore, differences in the thickness of 
mucosal linings arising from different physiologic factors such as age and stage of the menstrual 
cycle, vary from patient to patient. Therefore, these findings suggest that PEGylated NPs, created 
by pre-synthesis copolymerization, may avoid mucosal clearance while still providing adequate 
diffusion and penetration within the vaginal tissue. Both of these studies reveal the impact that 
two different copolymer blends can have on formulating mucus-penetrating NPs while 
eliminating the need of post-synthesis surface modification.30,37  
Transport dependence on NP formulation reactants 
The impact of residual reactants from NP synthesis was explored in relation to NP transport 
through the CVM.37,40,79 Surfactants that are typically used for NP synthesis, such as polyvinyl 
alcohol (PVA), are intrinsically mucoadhesive, and therefore post-synthesis residue may impede 
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NP transport through mucus. Given this, the effect of surfactants on CVM distribution was 
assessed by analyzing NP diffusion in human CVM specimens. PLGA NPs were synthesized 
with novel vitamin E surfactants that had been previously conjugated to a 1 or 5 kDa methoxy-
PEG-OH (PLGA/VP1K and VP5K, respectively), PVA surfactant alone, and  COOH-only 
modified (PS-COOH) or PEG-modified (2 kDa) PS NPs as controls.40 PLGA NPs synthesized 
using the VP1K surfactant exhibited no marked increase in CVM transport relative to 
unmodified COOH-only PS NPs.40 However, increasing the PEG molecular weight to 5 kDa 
significantly impacted diffusion. The MSD of PLGA/VP5K NPs in CVM was 210- and 33-fold 
higher than that of PS-COOH and PLGA/VP1K NPs, respectively. Moreover, VP5K PLGA NPs 
were found to be the most resistant to mucoadhesion relative to VP1K and traditional PLGA 
NPs, confirming the importance of and sensitivity to surfactant and PEG molecular weight on 
CVM diffusion. 40 
 
Given the correlation between neutral surface modification and enhanced mucus penetration, 
another study sought to investigate the effect of PVA alone on CVM transport.  Due to the 
hydrophilic and neutral nature of PVA, it was hypothesized that coating PLGA and PS NPs with 
PVA may enhance NP diffusion.79 Interestingly, PS NPs coated with PVA, regardless of 
concentration (0.01 or 1% w/v) or molecular weight (2, 6, or 25 kDa) remained immobilized in 
the CVM. When tested in fresh, undiluted human mucus samples, PS NPs that were synthesized 
with 2, 6, and 25 kDa PVA (1% w/v incubation concentration) had diffusion coefficients 23,000-
, 14,000-, and 10,000-fold lower than their theoretical values in water, respectively.79 The effect 
of increasing PVA molecular weight decreased mucoadhesion and therefore increased diffusion. 
While PLGA NPs formulated with PVA surfactants were immobilized in the CVM relative to the 
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surfactant-free NPs and PEG-PLGA NPs, these results suggest that the inclusion of PVA as a 
surfactant or surface modification may promote mucoadhesivity that can be tailored with 
changes in molecular weight or concentration.  
 
Summary of human CVM studies 
The use of human CVM affords the possibility to emulate a physiologically relevant mucosal 
environment and to use this environment to gain an understanding of how physicochemical 
parameters impact NP diffusion in the CVM. While in vitro studies that utilize human CVM 
studies provide an informative system, there are drawbacks to this methodology. Sources of 
human CVM are not always readily available, and adequate amounts of CVM required to study 
multiple diffusion parameters can be challenging to obtain. Furthermore, patient samples are 
often inherently different from one another. In spite of these drawbacks, utilizing human CVM is 
a relatively straightforward technique that allows for rapid data interpretation, which can be 
valuable to the design of NP formulations. With this technique, NP delivery vehicles can be 
precisely designed to obtain mucoadhesion (for retention) or mucus penetration (for distribution). 
By using human CVM, the reviewed studies were able to explore how NP size, formulation 
chemistry, formulation reactants, surface charge, surface-ligand density, ligand molecular 
weight, and surfactant may significantly impact NP diffusion in an environment closely 
corresponding to in vivo CVM conditions.  
 
b. SYNTHETIC MUCUS STUDIES 
Synthetic mucus formulations have been developed to study mucus rheology and the diffusion of 
small molecules and some delivery vehicles in vitro as a means to avoid the shortcomings of 
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human CVM.17,18,70 Although these mucus formulations are not obtained from humans, they are 
able to recapitulate critical mucus properties such as microstructure and viscoelasticity. Synthetic 
mucus has the ability to adequately simulate bulk mucus properties, even though it lacks critical 
components of a biologic system, such as innate physiological interactions and cellular-
molecular components. While the majority of studies have focused on the analysis of mucus 
microstructure,4,27,30,42,72 viral transport,11,24,43-45,71,81 or small molecule diffusion,71,81-83 limited 
studies have used synthetic mucus to assess delivery vehicle transport.  
 
Transport dependence on NP formulation chemistry 
Most recently, the interactions of dapivirine-loaded polycaprolactone (PCL) NPs were studied in 
a synthetic mucus environment.16,18 Polycaprolactone NPs encapsulating dapivirine were 
evaluated due to their potential application as microbicides, and their demonstrated 
mucoadhesivity, sustained-release, and retention within the CVM. To create synthetic mucus, 
mucin fibers were added to SVF (1.5% w/v) followed by bulk rheological analysis to confirm 
that the viscoelastic properties were comparable to human CVM.18 Using this in vitro model, it 
was observed that varying NP surface charge significantly contributes to altering the diffusion 
time across a 200 µL layer of SVF in an 8-well imaging chamber. In this system, negatively-
charged NPs exhibited the most rapid diffusion.18  
 
To expand on this work, the effect of NPs modified with cetyltrimethylammonium bromide 
(CTAB), poly(ethylene oxide) (PEO), and sodium lauryl sulfate (SLS) was assessed both in in 
vitro cell monolayers and ex vivo porcine vaginal mucosa, to increase dapivirine retention in the 
vaginal CVM.10  In cell monolayers comprised of CaSki vaginal epithelial cells, PEO-PCL NPs 
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exhibited the lowest apparent permeability coefficient of dapivirine (2.2 ± 0.2 cm·s-1 x 10
-6) 
relative to free dapivirine (3.0 ± 0.3 cm·s-1 x 10
-6), while CTAB NPs exhibited the highest 
dapivirine permeability coefficient (4.6 ± 0.5 cm·s-1 x 10
-6). In subsequent studies, ex vivo 
vaginal porcine tissue was utilized to further explore how these surface modifications impacted 
dapivirine retention and NP diffusion.16 Permeability coefficients obtained ex vivo followed 
similar trends, with PEO-PCL NPs exhibiting a very low dapivirine permeability coefficient (0.6 
± 0.2 cm·s-1 x 10
-6) and CTAB-PCL NPs diffusing more rapidly, with a dapivirine permeability 
coefficient of 3.0 ± 0.3 cm·s-1 x 10
-6, relative to PEO-PCL NPs and free dapivirine. These results 
suggest that PCL NPs modified with PEO have the strongest mucoadhesion, whereas CTAB-
PCL NPs diffuse more rapidly through the vaginal epithelium.16 
 
Transport dependence on NP modifying agent and surface charge 
Similar to the results obtained with human CVM, it was observed that NP modifying agent and 
surface charge significantly contribute to NP affinity for mucus.16 Interestingly, PEO-modified 
NPs exhibited enhanced mucoadhesion properties in this synthetic CVM system, which is in 
contrast to the aforementioned studies in which high molecular weight PEG (10-40 kDa) was 
utilized to decrease mucoadhesion.14,29,30 This discrepancy may be due to the difference between 
human and synthetic mucus, and highlights the complexity of NP-CVM interactions.  
 
c. TOWARD MORE REALISTIC IN VITRO SYSTEMS 
One of the main drawbacks of in vitro systems utilizing human or synthetic CVM is the 
challenge of accurately representing the in vivo environment, including the complex anatomical 
structure of the mucus and the underlying tissue that comprises the FRT. When delivered 
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topically, it is often desirable for NPs to traverse mucus, withstand mucus shedding, and 
penetrate to the underlying epithelial and stromal tissue, depending on the intended cell or 
pathogen target. To complement analyses provided by human or synthetic CVM models, 3D 
models that include polymer matrices and multi-cellular layers, representative of epithelial and 
stromal layers, have been created to provide a noninvasive and physiologically relevant 
environment in which to study transport parameters. While a comprehensive review of available 
cell culture models may be found in 74, hallmark studies relevant to FRT delivery include 
44,69,73,74,76,77,84,85. 
 
iii. Ex vivo transport studies 
In addition to human and synthetic mucus in vitro systems that have been employed to study NP 
transport, ex vivo models have been developed to gain insight into NP transport in the 
intravaginal environment. By integrating some of the attributes of in vitro and in vivo systems, ex 
vivo models can provide physiologically relevant tissue architectures, representative of the FRT 
microenvironment. In particular, porcine vaginal tissue has been used to investigate the 
mucoadhesive properties of NPs and other colloidal systems, as described in 41,86 . 
 
Similar methodologies have been used to investigate the efficacy of tenofovir-encapsulated 
chitosan NPs as a potential microbicide.87 Chitosan NPs were synthesized with varying 
diameters, with the smallest and largest NPs ranging from 188 to 900 nm. Due to the inherent 
bioadhesive properties of chitosan, it was hypothesized that NP mucoadhesion would be size-
dependent. It was found that NPs with smaller diameters were twice as mucoadhesive relative to 
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the larger NPs.87 These results are in agreement with previous work that found that PS NPs 
ranging from 200-500 nm exhibited more rapid diffusion relative to 100 nm NPs,22 suggesting 
that physical properties such as size and NP material (here PS or chitosan) can be used to tailor 
NP mucoadhesivity.    
 
While ex vivo systems provide a physiologically representative environment in which to study 
NP diffusion – having defined mucosal and underlying vaginal tissue layers – they still suffer 
from limitations, such as the inherent differences between animal and human tissue. 
Additionally, when studying diffusion in ex vivo models, there is an inability to temporally 
evaluate NP transport and clearance from the CVM, relative to vaginal fluid and tissue flux, 
since continual fluid exchange does not occur in these models. 
 
iv. In vivo transport studies 
Although in vitro systems provide a highly controlled environment, spatiotemporal knowledge is 
seldom derived from in vitro cell monolayer studies due to the two-dimensional limitations and 
inherent differences of in vitro systems relative to in vivo tissue. Additionally, an in vitro system 
is typically limited to one or two cells types, or is focused on mucus alone, providing a 
comparatively isolated and compartmentalized method to investigate NP diffusion and transport.  
As such, in vivo systems can address the limitations of in vitro as well as ex vivo models, and 
enable the comprehensive assessment of how alterations in NP formulations impact transport in 
the CVM. A more comprehensive evaluation is possible due to the ability of in vivo models to 
provide a realistic environment in which to study NP diffusion and transport, and to evaluate the 
19 
 
associated therapeutic efficacy within the FRT.  In particular, tissue histology from in vivo 
studies provides knowledge of how drug delivery vehicles diffuse and distribute throughout 
vaginal tissue.  Such in vivo studies enable investigators to study the diffusion kinetics within the 
FRT as an integrated system, which provides a more thorough evaluation of how NP delivery 
systems interact with the CVM and vaginal tissue. With this in mind, the complexity of the in 
vivo environment requires the consideration of more parameters to rationally design NP delivery 
vehicles.  
 
a. EFFECTS OF SURFACE-MODIFICATION TYPE AND DENSITY ON IN VIVO 
TRANSPORT 
One way to improve intravaginal penetration and retention of polymeric NPs in vivo has been to 
conjugate NPs with ligands to modulate physicochemical properties, such as surface charge and 
hydrophobicity. To explore the effect of conjugating biotinylated PEG (2 kDa) to avidin-
modified PLGA NPs, a murine model was used to measure the vaginal retention of surface-
modified NPs.12 Nanoparticle groups including avidin-only and avidin-PEG NPs exhibited up to 
5-times increased vaginal retention, relative to unmodified NPs. Furthermore, PEG NPs were 
found within the submucosal stromal cells and epithelium, suggesting that these NPs 
efficaciously penetrate the CVM to the underlying basal immune cells. Relative to avidin-only 
and unmodified NPs, PEG NPs were also found at higher concentrations throughout the CVM up 
to 6 hr post-administration.12  
 
Building upon this study, PLGA NPs with a variety of PEG modification densities (2, 3, 5, 8, 10, 
and 25 wt%) were synthesized to study the impact of modification density on tissue 
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penetration.34 NP synthesis was accomplished by blending a diblock copolymer of 5 kDa PEG 
and PLGA (5.6, 20, and 45 kDa), followed by confirmation of PEG-modification densities with 
H-NMR. The resulting NPs made from PEG-PLGA copolymers were tested in a murine model 
to assess NP diffusion and distribution within the CVM. Unmodified PLGA NPs were unable to 
fully penetrate vaginal rugae in the outermost epithelial layer, and remained sequestered in the 
outer mucus layer. Similarly, PEG surface densities below 10% were inefficient in penetrating 
the outer mucus layer. However, high surface coating densities spanning 10-25% effectively 
diffused through the outer mucus layer and distributed evenly throughout the rugae. Moreover, 
PEG-PLGA copolymer NPs with 25% PEG surface density exhibited significantly more surface 
coverage than all other NP formulations.34  
Comparing these results with previous in vitro work, where it was observed that PLGA NPs 
partially coated (10 wt%) with 5 kDa PEG achieved enhanced diffusion relative to unmodified 
PLGA NPs,14 a coating density of 10-25% was needed to achieve improved CVM diffusion in 
this in vivo study.34 This difference suggests that the minimal surface coating density required for 
diffusion within the CVM and uniform coverage of vaginal tissue may be underestimated by in 
vitro studies.  
To further characterize the impact of NP surface modifications on CVM transport in vivo, PS 
NPs were modified with various molecular weight PEG molecules, ranging from 5 to 40 kDa, 
and surface modification densities (1.3 – 3; area covered by PEG/total surface area).26,29 NPs 
densely coated with 40 kDa PEG exhibited the most effective transport and distribution through 
CVM (5-10 min post-administration). Densely modified NPs were shown to more uniformly 
cover the epithelium, independent of PEG molecular weight, suggesting that high molecular 
weight PEG can improve NP penetration and distribution through human CVM. These results 
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confirm previous in vitro work,13,16,18,22,23,29-31,34,35,37,79 that ligand molecular weight and surface 
density play key roles in tailoring the mucoadhesive/muco-inert properties of NPs.  
In a separate in vivo study, the effect of coating PCL (14.8 kDa) NPs with a tribock polymer of 
poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO) (PEO-PPO-PEO), relative to the 
typically assessed low molecular weight PEG (2-10 kDa) was evaluated.15 In female ICR mice, 
PEO-PCL NPs were localized in vaginal and uterine tissues 2 hr post-administration, penetrating 
as much as 40 µm through the vaginal tissue and distributing throughout the rugae. When 
comparing the diffusion coefficients of these PEO-PCL NPs (high MW PEO) to previously 
studied PEG-modified PS NPs (2 kDa PEG),22 the PEO-PCL NPs were only 3-7 times slower, 
suggesting that in spite of increased PEG molecular weight, the PEO-modified NPs adequately 
traversed the CVM and penetrated the vaginal epithelium.  
b. EVALUATION OF TRANSPORT OF UNMODIFIED NPS 
In parallel with in vitro, ex vivo, and in vivo studies that have demonstrated enhanced delivery of 
surface-modified, relative to unmodified NPs, recent work has shown that penetration and 
retention of polymeric NPs may still be attained with unmodified NPs. The transport and 
efficacy of unmodified siRNA PLGA NPs were assessed within the FRT by intravaginally 
administrating sub-200 nm diameter fluorescently-labeled NPs to female ICR mice.33 NP 
distribution was assessed over 7 days, and the analysis of tissue cross-sections revealed regions 
of the vaginal tract in which NPs penetrated 75 μm beneath the lumen. Furthermore, time-course 
studies using multiphoton microscopy revealed that NPs had penetrated up to 120 μm below the 
luminal surface and were retained as long as 7 days post-treatment.33 These results suggest that 
unmodified NPs penetrated the CVM and distributed throughout the vaginal tract to deliver a 
sufficient therapeutic payload. Although NP penetration and retention were observed to induce 
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therapeutic efficacy, the transport of surface-modified NP groups was not measured in 
comparison. The question whether surface modification improves penetration and efficacy 
relative to unmodified PLGA NPs requires further investigation.   
c. EFFECTS OF SURFACTANT ON IN VIVO TRANSPORT 
Concurrent with the described work that has correlated surface modification to diffusion and 
distribution in the FRT, other studies have explored the effect of utilizing a biocompatible 
surfactant, pluronic F127, to produce mucus penetrating particles.36 To investigate the improved 
chemotherapeutic efficacy obtained from these particles, a commonly used chemotherapeutic, 
paclitaxel, was encapsulated in the F127-modified NPs. When administered intravaginally in 
TC-1 tumor bearing mice, unmodified NPs aggregated within the vaginal lumen, preventing 
diffusion to the underlying epithelium, even after 20 hr.  In contrast, NPs coated with F127 
demonstrated significantly improved distribution and diffusion, uniformly dispersing through the 
CVM and penetrating to the underlying epithelial tissue. This enhanced diffusion translated to 
improved therapeutic efficacy, with F127-modified NPs reducing tumor growth by 
approximately 93% relative to the untreated control group, while unmodified NPs reduced the 
tumor load by only 42%. Moreover, survival time was extended to 11 and 19 days, for 
unmodified and surface-modified NPs respectively, relative to a survival time of 9 days for the 
untreated mice.36 This study highlights the use of an unconventional surface modification to 
increase the chemotherapeutic efficacy of intravaginally administered drugs. 
d. EFFECTS OF MUCUS PROPERTIES AND ADMINISTRATION SOLUTION ON IN 
VIVO TRANSPORT 
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While many of these in vivo (and in vitro/ex vivo) studies have focused on surface ligands and 
surfactants to enhance NP distribution, other methods have assessed the role of mucus properties 
to provide enhanced NP delivery to the FRT. Since both PEGylated PS and PLGA NPs have 
shown varying degrees of efficacy over a range of PEG molecular weight and surface densities, a 
murine model was used to study the conditions in which mucus-penetrating PEG NPs may be 
delivered most effectively.21 In this study, PS and PLGA NPs modified with 2 kDa PEG were 
administered intravaginally in hypotonic media, mimicking advective transport. To quantify the 
distribution of these NPs in vivo, vaginal and ectocervical tissues were excised and imaged via 
fluorescence microscopy. Both PEG-modified PS and PLGA NP groups, administered in 
hypotonic media, were shown to uniformly accumulate and coat the entire vaginal epithelium 
after only 10 min. Furthermore, similarly administered surface-modified NPs, penetrated more 
than 100 μm into the CVM within 10 min. As a function of surface-modification, images 
revealed that 88% and 86% of the tissue surface was covered with PEG-modified NPs, while 
only 30% and 36% coverage was attained with unmodified NPs in vaginal and ectocervical 
tissue respectively.21  These studies corroborate other in vitro and in vivo data to suggest the 
significant impact PEGylation has on penetration/distribution kinetics in CVM, and provide 
insight into the impact of administration method and conditions on NP diffusion. Exploiting the 
more rapid fluid influx of NPs to the vaginal epithelium, observed using hypotonic conditions, 
may provide an effective administration technique that relies on advective transport rather than 
diffusion alone.  
 
Subsequent work,88  building upon 21, investigated the impact of fluid osmolality by utilizing 
modest to high hypotonic solutions to administer PEG-modified (5 kDa) PS NPs to the murine 
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vaginal tract.88 When delivered in both high and low hypotonic solutions (20 and 220 mOsm/kg, 
respectively) PEG NPs were shown to rapidly penetrate the CVM and vaginal lumen, covering 
88% and 76% of the underlying vaginal epithelium. This was a significant increase relative to the 
isotonic solution (294 mOsm/kg), in which PEG NPs only covered 60% of the vaginal 
epithelium. In addition to enhanced distribution and penetration, PEG-modified NPs exhibited 
higher vaginal retention 1 hr post-treatment when delivered in a hypotonic solution. In non-
ambulatory mice, 69% and 83% of NPs were retained for isotonic and hypotonic solutions, 
respectively, while for ambulatory mice, the retention rate for the isotonic solution was 22%, and 
remained somewhat constant (75%) for the hypotonic solution. In both cases, PEG NPs 
administered in a hypotonic solution were retained within the vaginal tract for longer durations, 
indicating that the rapid delivery of PEG NPs to the vaginal surface using a hypotonic solution 
promotes NP retention.88 These results confirm the enhanced distribution and penetration effects 
from using hypotonic solutions to administer NPs intravaginally. They also underscore that 
administration solution, in addition to NP surface-modification, may have a significant impact on 
in vivo mucus properties, impacting drug delivery and distribution through the CVM. 
e. EFFECTS OF POLYMER TYPE ON IN VIVO TRANSPORT 
In addition to assessing surface-modifications and delivery conditions, different polymeric 
delivery vehicles have been evaluated in murine models.25 A novel formulation, comprised of 
phenylboronic NPs, was studied to improve NP mucoadhesion within the FRT.25  Due to the 
affinity of phenylboronic acid to form stable cyclic ester bonds with mucin, phenylboronic acid 
rich-NPs (PBNPs) were seen as an attractive option to formulate mucoadhesive delivery 
vehicles. Moreover, it was believed that modifying PBNPs with sodium sulfate would increase 
colloidal stability and form stable bonds with mucin fibers. In preliminary in vitro studies, 
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PBNPs surface-modified with sodium sulfate at 5 and 10 wt% (PBNP-S5 and -S10) exhibited 
increased mucin adsorption at vaginal pH relative to unmodified PBNPs.25 Following 
intravaginal administration in mice, both PBNPs and PBNP-S5 had increased vaginal retention 
up to 48 hr post-treatment, whereas the amount of control solution significantly decreased 
between 0 and 6 hr post-treatment. While the in vitro and in vivo results show nuanced 
differences in mucoadhesion, these studies highlight the similar relationships that may govern 
NP distribution with different polymers. Moreover, these results confirm that differences 
observed within carefully controlled in vitro experiments may be less impactful in an in vivo 
environment where multiple factors govern distribution.  
f. EFFECTS OF THE REPRODUCTIVE ENVIRONMENT ON IN VIVO TRANSPORT 
While the focus of this chapter has been to convey design factors that can affect NP distribution 
and transport through the CVM in the FRT, it is also important to note that natural physiological 
changes in the CVM may affect NP diffusion. When translated to clinical application, a variety 
of differences exist in the human reproductive environment, contributing to increased variation 
of the FRT characteristics between patients. For example, age, hormone levels, and menstruation 
cycle are known to have a significant impact on CVM rheology and thickness, as well as the rate 
of vaginal fluid clearance.3,4,42 To explore the impact of menstrual cycle on NP distribution, an 
ex vivo experiment was conducted using CVM that had been excised from estrus phase mice or 
from mice that had been pre-treated with a progestin to mimic the diestrus phase of thicker CVM 
secretions.78 Using this model, the diffusivities of PS NPs surface modified with PEG (2 or 5 
kDa) were assessed, highlighting the variation in NP diffusion as a function of estrous cycle. In 
estrus phase vaginal tissue, 70% of PEG-NPs exhibited higher effective diffusivities through the 
CVM relative to all NP formulations administered to diestrus phase mice. Furthermore, PEG-
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NPs in diestrus phase CVM had a MSD of at least 30-fold less than the same NPs in estrus phase 
CVM. From the lower effective diffusivities of PEG-NPs in diestrus phase CVM, it was deduced 
that NP movement is primarily due to thermal fluctuations of the mucus, and that NPs were 
likely trapped within the mucus mesh as a result of steric hindrance.78 
g. SUMMARY OF IN VIVO STUDIES 
The reviewed in vivo studies highlight the complexities associated with the rational design of 
intravaginal NP delivery systems. Key polymeric NP parameters that have been evaluated in 
controlled in vitro conditions include surface modifying agent, surface coating density, size, and 
surface charge. When evaluating NP design in the FRT in vivo, these parameters must also 
include variations between menstrual cycle phases, method of administration, vaginal fluid 
clearance and NP retention, homogeneous distribution throughout vaginal tissue, and penetration 
of NPs to the vaginal lumen and rugae. The information obtained from in vivo transport studies 
provides for a more detailed understanding of the impact that more realistic and varied 
conditions present in the FRT, have on NP transport and efficacy through the CVM. Moreover 
these studies enable more complex correlations that identify factors that differ between benchtop, 
and translatable systems, to identify factors that have the most significant effect attaining 
distribution and resulting efficacy in the FRT NP transport and efficacy through the CVM. 
C. MATHEMATICAL MODELING OF SMALL MOLECULE DIFFUSION WITHIN 
THE FRT 
Mathematical modeling has been applied in the field of intravaginal drug delivery to gain insight 
into how FRT physiology impacts drug diffusion, transport, and dosage regimens. Mathematical 
models provide a means to efficiently test drug and molecule diffusion properties, simulating 
experimental conditions that might otherwise be challenging, labor-intensive, and inefficient to 
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replicate at the bench. Yet to generate meaningful outputs from such models, the functional 
relationships must reflect the associated biology and the input parameters must be accurate. In 
particular, key input parameters such as diffusion and drug or delivery vehicle partition 
coefficients, necessary to model transport through the CVM, are typically derived and validated 
from experimental analysis.  
i. Application of mathematical modeling 
The modeling of drug diffusion within the FRT has historically focused on drug flow and 
distribution along the vaginal canal.3,5,42,52,89 Recently, mathematical modeling has been applied 
to assess molecule transport and distribution through the surrounding vaginal tissue and 
mucosa.5,42,45,71,81,90  Even more recently, with the advent of drug delivery vehicles and 
microbicides, has the value of mathematical modeling for reproductive applications expanded. 
The development of microbicides for prophylactic and therapeutic approaches has seen 
significant growth in terms of developing drug delivery platforms to improve intravaginal 
delivery against sexually transmitted infections.11,17 Some of these platforms, which are topically 
applied to the vagina, including intravaginal rings, films, gels and most recently fiber meshes, 
have the capacity to provide tunable release of therapeutic agents that diffuse through the vaginal 
epithelium to the underlying stroma. In the near future, it is expected that mathematical modeling 
will also provide insight into NP-mediated drug delivery through the CVM. 
 
ii. Modeling of drug molecule diffusion 
Pioneering studies developed various mass transport equations that describe the PK and PD data 
of small drug molecules diffusing through the CVM after topical application (Table 2). Studies 
by Katz et al. explored mathematical modeling as a tool to better elucidate the parameters 
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governing intravaginal drug delivery. The group developed a multi-compartmental model to 
study the PK and PD behavior and diffusion of the antiretroviral tenofovir in the CVM as it 
released from an intravaginal gel.5 A series of coupled, partial differential equations 
characterized the transport of tenofovir through each layer of the mucosa (Table 2, Eqn. 1). The 
model incorporated equations to evaluate the subsequent uptake and clearance of tenofovir into 
the vascular and lymphatic systems once it penetrated through the mucosa. Initial studies 
conducted with this model focused on optimization to fit experimental PK data, and the 
predictive model outputs were found comparable to empirical data. From this analysis, the effect 
of differing biologic conditions between the cervicovaginal tissue layers, as well as the time 
required to achieve efficacious levels of therapeutic payload, was evaluated and confirmed when 
compared to concentrations measured from vaginal tissue biopsies.5  
 
This multi-compartmental model was extended in 91 , to account for natural variations in the 
vaginal canal, and to include convective drug transport due to spreading of the application gel 
(Table 2, Eqn. 3). A subsequent study conducted a global sensitivity analysis on this model using 
Sobol indices to further understand how variations in parameters, which describe the application 
gel and the physiologic environment, cause disturbances in the model output.90  From this 
analysis, it was observed that the model output was most sensitive to the parameters 
characterizing the initial drug concentration in the application gel, the partition coefficient of 
tenofovir in the epithelium, and the rate constant at which the gel was diluted due to vaginal 
fluid. Very recently, a pair of coupled mathematical models building upon the work of 5,92 
simulated the release of tenofovir and tenofovir disoproxil fumarate (TDF), which are 
structurally similar molecules, from PLGA electrospun fibers in the FRT (Table 2, Eqn. 2).93 The 
29 
 
results indicate that factors such as antiviral diffusivity, mesh thickness, fiber diameter, and 
geometry can be simulated to create an accurate model that distinguishes the very different 
release profiles of tenofovir and TDF observed in vaginal tissue. 
 
A comparative study was conducted by Katz et al.3 to highlight the fundamental mass transport 
principles and applications related to the diffusion and convection of drugs and small molecules 
through the vaginal environment (Table 2, Eqn. 1).3,82,89,91 The work focused on the use of 
models to investigate the PK and PD of tenofovir, and its associated derivative, TDF, when 
topically delivered to the vagina using either a gel3,91 or intravaginal ring,3,89 with differing 
dosage regimens. The model showed that the use of intravaginal rings created an enhanced 
accumulation of activated TDF in the stromal compartment that was maintained for a prolonged 
duration of weeks to months. Conversely, gels achieved an equivalent concentration of active 
agent in the stroma in less than one day; however, it was necessary to apply the gel repeatedly to 
maintain this concentration for longer than 24 hr. This study demonstrated how a model can be 
utilized to characterize the transport behavior of small molecules and, furthermore, to identify 
efficacious delivery modalities for specific antiviral agents.3  
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Table 2.  Summary of mass transport equations used to model molecule diffusion in the FRT. 
 
 Reference Model Model Description 
1 
Katz et 
al.3,5,82,90 
 
𝜕𝐶𝐺
𝜕𝑡
= 𝐷𝐺
𝜕2𝐶𝐺
𝜕𝑥2
− 𝐾𝐷𝐶𝐺 
𝜕𝐶𝐸
𝜕𝑡
=  𝐷𝐸
𝜕2𝐶𝐸
𝜕𝑥2
 
𝜕𝐶𝑆
𝜕𝑡
= 𝐷𝑆
𝜕2𝐶𝑆
𝜕𝑥2
− 𝐾𝐵𝐶𝑆 
Multi-
Compartmental 
Model for the 
Diffusion of 
Tenofovir 
(Matlab) 
2 
Halwes et 
al.93 
𝜕𝐶
𝜕𝑡
= 𝛻 ⋅ (𝐷𝐸𝛻𝐶) 
𝜕𝐶
𝜕𝑡
= 𝛻 ⋅ (𝐷𝑆𝛻𝐶) − 𝑘𝐿𝐶 
Multi-
Compartmental 
Model for the 
Diffusion of  TDF 
(Matlab) 
3 
Gao et 
al.91 
𝜕𝐶𝐸
𝜕𝑡
=  𝐷𝐸 (
𝜕2𝐶𝐸
𝜕𝑥2
+ 
𝜕2𝐶𝐸
𝜕𝑦2
) − 𝐾𝑜𝑛 {𝐶𝐸∅𝐸 −
𝐶𝐷𝑃
𝑟
}
+ 𝑘𝑜𝑓𝑓𝐶𝐷𝑃 
 
𝜕𝐶𝑆
𝜕𝑡
=  𝐷𝑆 (
𝜕2𝐶𝑆
𝜕𝑥2
+ 
𝜕2𝐶𝑆
𝜕𝑦2
) − 𝐾𝐵𝐾𝑆
− 𝐾𝑜𝑛 {𝐶𝑆∅𝑆 −
𝐶𝐷𝑃
𝑟
} + 𝑘𝑜𝑓𝑓𝐶𝐷𝑃 
Convective Drug 
Transport 
(Matlab) 
4 Lai et al.45 
𝜕 ?⃗? 
𝜕𝑡
= 𝐷
𝜕2?⃗? 
𝜕𝑧2
± 𝑓 (?⃗? (𝑧, 𝑡)) ± 𝑔 (?⃗? (𝑧, 𝑡)) 
 
Smoluchowski 
Encounter Rate 
(not disclosed) 
5 Lai et al.81 
𝜕𝑢
𝜕𝑡
=  𝐷𝐴𝑏0
𝜕2𝑢
𝜕𝑧2
 
Stochastic Viral 
Diffusion Model 
(not disclosed) 
 
 
 
iii. Modeling of diffusion of antibodies 
Mathematical models have also been used to study the transport and diffusivity of biological 
molecules, such as antibodies, through the CVM. Antibodies have recently emerged as a 
prophylactic approach to combat viral infection within the FRT. In conventional therapy, 
antibodies have been utilized to elicit a targeted immunogenic response.81 However, antibodies 
can provide an additional means to prevent viral infection. Antibodies can reduce the diffusive 
flux of a given virus, such as HIV, by binding to receptors on the individual virions and to mucin 
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fibers within the CVM.45,71,81 This coupled binding has provided a virus trapping system, in 
which virus diffusion is hindered, prior to reaching the vaginal stroma.81   
 
Studies conducted by Lai et al. have complemented experimental work, by utilizing deterministic 
mathematical models to characterize virus immobilization and to gain insight into the most 
effective parameters that reduce virus diffusion (Table 2, Eqn. 5)81 The group developed a 
mathematical model to study the impact that certain parameters, such as the rate of mucin 
binding and affinity for virion binding, have on prophylaxis. Immunoglobulin G (IgG) was 
chosen due to its proven efficacy in saturating the CVM and hindering HIV diffusive flux. The 
model results indicate that to maximize virus immobilization and minimize viral diffusive flux 
and thus infection, IgG antibodies must exhibit a high affinity for virion binding and a weak 
affinity for mucin binding.  
 
In another study, this group applied a mathematical model to evaluate the potential effects of 
secretory immunoglobulin A (IgA) in the CVM as a means to agglutinate and prevent HIV 
transmission (Table 2, Eqn. 4).45 The model investigated the mechanisms by which secretory IgA 
binds to HIV, causing agglutination and aggregation and thus preventing infection. Experimental 
data were used to simulate virion collision kinetics in a physiologically accurate environment. 
Outputs from the model suggest that, regardless of viral load, secretory IgA-related agglutination 
is most likely not the primary mechanism by which viral and pathogenic infection is mediated. 
Furthermore, the model implies that this agglutination phenomenon is most likely effective 
against pathogens where diffusion is characterized as other than Brownian motion or has a high 
propensity for collision and encounter rates.45  
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iv. Definition of key parameters 
Expanding modeling capabilities to more complex environments requires that predictive 
deterministic and mechanistic models be applied and adapted to fit empirical data, such that the 
PK and PD properties of small molecule drug diffusion and transport may be better understood. 
Data gathered empirically in in vitro tissue mimics, in vivo, or ex vivo tissue models are therefore 
critical to extrapolate key transport parameters. In particular, when building a model to predict 
drug delivery within and through the CVM, whether it be small molecule release from a 
topically-applied platform or free drug delivery, the associated parameters must be precisely 
defined because the model output is dependent upon and sensitive to these parameters. Further, 
the geometry and assumptions made about the environment when creating a model are critical to 
its effectiveness. In studies where small molecule diffusion through mucus membranes has been 
modeled,3,4,42,71,89 it was found that the orientation of the mucin fibers as well as mucus porosity 
play critical roles in defining models that yield accurate simulations. The vaginal mucosa, the 
physiologic effects of menstruation on fluid volumes and pressures within the vaginal canal, the 
cell densities of the lamina propria and stromal layers, and the properties of the mucus gel itself, 
significantly impact diffusive transport. These characteristics need to be accurately described by 
the model parameters and functional relationships. In addition to having an appropriate 
understanding of the environment being modeled, it is also necessary to define the 
physicochemical and PK parameters of the therapeutic agent of interest. Further, in terms of 
delivery platforms, relevant parameters for fiber meshes include mesh thickness, fiber diameter, 
and geometry, while for NP-based transport, the characteristics of the delivery vehicle include 
lipophilicity, surface charge, molecular weight or average size, and diffusion coefficient. These 
parameters are typically measured and extrapolated from empirical data, as illustrated in 5,91 .  
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v. Summary of modeling of small molecule transport through the FRT 
Although the mathematical modeling of small therapeutic molecules in the FRT, and more 
specifically through CVM, is in its nascent stages, substantial progress has been made to date. 
The modeling work has advanced the understanding of the characteristics of small molecule 
diffusion as well as the associated PK and PD behaviors in the complex environment of the FRT.  
Accounting in more detail for the nonlinear characteristics of cervical mucus as well as natural 
variations in the vaginal canal may be necessary to obtain further insights. Modeling different 
cell types and their interactions, such as stromal and immune cells, may help to fine-tune the 
therapeutic response.  Tailoring model parameters for different drugs and therapy modalities 
would help to move this work toward predictive capability. In particular, more mobile delivery 
vehicles, such as polymeric NPs, could encapsulate and protect active agents from unwanted 
cellular interactions or degradation, and carry them through the mucosa. Mathematical modeling 
could be applied to tailor such NPs to have mucoadhesive properties, to “stick” to the mucus 
layer, slowly releasing drug at this location, or to utilize muco-inert features to penetrate the 
epithelium and release drug within the stroma. Further, the coupling of various models, such as 
drug release from electrospun fibers with drug diffusion within the FRT,93  holds the promise for 
an integrated understanding of therapeutic efficacy. Ultimately, the development of modeling 
frameworks that include user, therapeutic, and physiological characteristics may offer practical 
tools to complement current clinical approaches by informing therapeutic design that is 
personalized to individual patient needs. 
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D. UTILIZING EMPIRICAL STUDIES AND MATHEMATICAL MODELING AS 
COMPLEMENTARY TOOLS TO INFORM NP DESIGN 
Topical drug delivery to the FRT is a burgeoning field with many applications spanning 
chemotherapeutic treatments to microbicidal interventions. Polymeric NPs have demonstrated 
promising potential for efficacious delivery to the FRT, by enhancing the diffusion of 
encapsulated agents through the CVM, in addition to imparting tailorable mucosal interactions. 
As has been addressed in this chapter, several experimental approaches – comprised of in vitro, 
ex vivo, and in vivo systems – have been utilized to characterize NP delivery and transport 
through the vaginal mucosa. From these studies, it can be appreciated that NP-CVM interactions 
are complex, and that the parameters governing these interactions must be considered to 
rationally design efficacious NP delivery systems.  
 
Several factors may enhance or impede NP diffusion in the CVM. The in vitro and ex vivo 
studies discussed highlight that NP diffusion through the mucosa is dependent on ligand choice, 
modification density, and molecular weight. Expanding upon these studies, in vivo experiments 
have provided more complex environments in which to assess NP transport and diffusion. In 
addition, in vivo studies have shown that NP transport varies as a function of the administration 
method (here tonicity and advection) and menstrual cycle phase at the time of administration. 
Furthermore, these studies utilize a physiologically relevant environment to provide 
spatiotemporal details that relate NP diffusion to penetration depth and homogeneity of NP 
distribution within vaginal tissue.  
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Despite the relationships elucidated by in vitro, ex vivo, and in vivo experiments, one of the 
challenges facing experimental systems is the scarce number of specimens available. The limited 
number of samples – whether human or synthetic mucus, ex vivo tissue, or in vivo animal models 
– are unable to meet the experimental needs to test the vast number of possible parameter 
variations involved in NP design. Even if human specimens were plentiful, iterative experiments 
would be inefficient to evaluate single or multiple parameter variations across every parameter of 
interest. Furthermore, variations exist between human CVM samples for in vitro studies, ex vivo 
tissue, and in vivo animal tissue, which make it difficult to translate or scale-up for seamless 
comparison to the human FRT. Additionally, synthetic mucus and tissue samples derived from 
animals  lack some of the complex physiological properties that are unique to the human FRT.   
 
Complementary to experimental models, mathematical modeling presents a platform that enables 
a systematic assessment of how different mechanisms and interactions affect diffusion and 
transport within the CVM. Mathematical models have been used to study the release 
characteristics of topically applied delivery systems (e.g., intravaginal rings, gels) and small 
molecule transport through the CVM (antibodies, antivirals). However, to our knowledge, there 
have been no mathematical models that investigate the impact that the mucosal diffusion of NPs 
has on the delivery or efficacy of therapeutic encapsulants, nor that distinguish NP diffusion 
from the pharmacokinetics of therapeutic payload release. Moreover, as the field expands to 
include more labile biological molecules (e.g., oligonucleotides, peptides, proteins), 
physiological conditions will have an increased impact on molecule activity as a function of 
release and tissue/intracellular location. Similar to drug delivery, individual biologic agent 
characteristics will vary as a function of environment, but may more rapidly be affected based on 
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release, binding, and internalization. Furthermore, for next-generation multipurpose delivery 
platforms – where multiple active agents, multiple types of delivery vehicles, or both are 
combined – it will be beneficial to elucidate these interactions alone and in combination with 
predictive and validating design tools.  
 
Although mathematical modeling faces difficult challenges, such as maintaining biological 
relevance and minimizing computational costs, it is the primary means through which complex 
system analysis can be performed to gain further insight into in vitro, ex vivo, and in vivo data. 
Models can be built and tailored to integrate the knowledge acquired from experimental data and 
to enable the effective assessment of variation in system parameters. Furthermore, while current 
experimental techniques are often limited to evaluating one, or at most two different parameters 
in one study, modeling provides a high-throughput means to systematically evaluate multiple 
parameters.  
 
Given the complexity of the FRT environment, more comprehensive models may be required to 
accurately simulate vehicle parameters to effectively model NP transport. In particular, a model 
that integrates ligand density, molecular weight, and hydrodynamic NP size would be beneficial 
to account for variation in diffusion through the different layers and tissue types of the FRT. 
Furthermore, ligand (e.g., molecular weight, charge, hydrophobicity, affinity) and polymer types 
used to fabricate delivery vehicles may be characterized and included in the model framework to 
highlight how these molecules interact with the mucosa. For instance, relationships between 
characteristics such as surface charge, hydro- or lipophilicity, propensity or rate of mucin 
binding, and self-aggregation, may be of interest, as these have been observed to affect diffusive 
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transport. Modeling these NP properties in relation to their mucosal interactions would result in a 
more comprehensive model and, thus, more translatable and insightful simulations.  
 
As highlighted by some of the in vivo work summarized here, and in addition to the properties 
inherent to NP formulation and characterization, the method of NP administration also impacts 
transport. The in vivo studies have shown that the tonicity and osmolarity of the topically-applied 
NP suspension have a significant impact on NP penetration and transport in the mucosa and 
vaginal tissue. More specifically, the tonicity and osmolarity dictate the predominant method of 
transport – usually a combination of bulk fluid flow and diffusion − and thus the rate of NP 
transport and vaginal distribution. Despite this impact, these parameters have only been 
investigated in limited studies. Incorporating administration properties and methodology into 
predictive mathematical models may provide more insight into the extent of interdependency 
between NP properties and administration method.  
 
In addition to NP-specific characteristics and delivery vehicle administration conditions, the 
biological and structural properties of the mucosa itself can affect NP diffusivity, and are thus of 
significant interest to model. Alterations in mucin fiber arrangement and mucus viscosity are 
related to stage of menstrual cycle, age, and hormone levels, all of which vary from patient to 
patient. These patient-specific dependencies, make it difficult to characterize their effects with 
the limited in vitro and in vivo experimental techniques and specimens currently available. 
Therefore, including these parameters in a mathematical model may enable a more thorough 
understanding of how anatomical and physiological properties impact the fate of NP delivery 
systems, which has yet to be fully characterized empirically. Additionally, future work may 
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focus on addressing limitations such as emulating vaginal fluid clearance and the variations in 
mucus composition and tissue thickness, which prove difficult to recapitulate in vitro. 
 
The current knowledge gaps or limited experimental data may be informed by mathematical 
modeling. Comparisons across experimental model types (e.g., ex vivo murine with in vivo 
murine with human clinical trials) may be made, and explored in greater depth via mathematical 
models that are used to collect, retain, and refine this information across studies. This integrative 
approach would more readily enable the rational design of tailored and personalized delivery 
systems that meet patient-specific needs. The evolution and connectivity of these models could 
have significant clinical impact, identifying new ways to target FRT tissue, and increase the 
efficacy of next-generation delivery systems.  
In addition to NP characteristics, administration methods, and patient-specific features 
that broadly govern delivery, the studies conducted to date highlight select choices in NP design 
features. For example, currently, the majority of NP diffusion studies have investigated the use 
of muco-inert (PEG) or mucoadhesive (chitosan) surface-modifications. However, within the 
field of NP delivery, other modifying agents have been utilized such as cell penetrating peptides 
(CPPs),1,2,28 which have intracellular targets and promote rapid cellular internalization. As new 
biologic delivery needs will necessitate both transport and cell internalization, the balance 
between features imparted by multiple ligand types will be valuable to explore. To date, there are 
few studies that address how NP diffusion varies as a function of such ligand modification, with 
only cursory studies investigating overall surface charge. In addition to peptides that promote 
ubiquitous internalization, specific ligands that target epithelial or immune receptors, may be of 
interest for reproductive cancers or to prevent virus uptake, or to provide virus-like targeting to 
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host tissue. As such, next-generation delivery vehicles may rely on combinations of different 
ligands, with different molecular weights and characteristics than the typically modeled PEG. 
Moreover, tunable surface features may enable temporal changes to carriers (e.g., pH-responsive 
ligand release or sheddable ligands) that change carrier transport as a function of location and 
time. As this type of drug delivery has applications in both cancer chemotherapy and 
microbicides, it would be advantageous to have an improved understanding of how these NP 
delivery systems transport and exert their effect within the FRT. 
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II. Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer 
 
 
Adapted From: 
Sims LB, Curtis L, Frieboes H, Steinbach JM; Enhanced Uptake and Transport of PLGA-modified  
Nanoparticles in Cervical Cancer Cells; April 22, 2016; Journal of Nanobiotechnology2 
 
 
A. CLINICAL SIGNIFICANCE AND BACKGROUND 
Cervical cancer is the third most common gynecologic cause of cancer associated with patient 
fatalities. Approximately 13,000 new cases of invasive cervical cancer are diagnosed yearly, of 
which 30 % prove fatal. In the US, cervical cancer primarily afflicts women younger than 50; 
however, in countries without established screening and prevention programs, cervical cancer 
remains the second most common type of cancer and cause of death among all female cancers94-
96. Screening tests and vaccines have contributed to a decrease in cases; to date, there are 3 
approved vaccines against cervical cancer. These vaccines, Gardasil®, Gardasil® 9, 
and Cervarix®, aim at preventing cancers originating from HPV types 16 and 18, which are 
attributed to ~70% of cervical cancers 97. Yet despite this efficacy, the vaccines only protect 
against a subset of all known HPV strains 97-99. The inadequacy of vaccination, coupled with the 
fact that vaccination is not widespread 98,99, maintains the risk of cervical cancer as a fatal 
disease.  
Relative to the success of prophylactic vaccines, ineffective treatment options exist for 
established HPV infections and cervical cancer originating from HPV. This is primarily 
attributed to multidrug resistance and chemotherapeutic side effects. Despite early stage tumor 
identification and established eradication methods including surgery and radiation, the adverse 
side effects of these treatment strategies often result in negative gynecologic and obstetric 
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outcomes. In comparison to surgical and radiation challenges, even systemic chemotherapy 
results in relatively low transport efficiency, resulting in high chemotherapeutic doses needed to 
target mucosal and epithelial tissue 36,100-102. Due to the high systemic toxicity induced by 
systemic chemotherapy, new treatment strategies are urgently needed. 
In addition to these clinical challenges, successful therapeutic agent delivery to the tumor 
microenvironment requires minimizing agent degradation and excretion, avoidance of 
immunogenic interactions, adequate penetration and distribution throughout the tumor tissue, 
cellular uptake and internalization, and sufficient cytotoxicity 103. United States Food and Drug 
Administration (FDA)-approved materials may be selected as nano-scale drug carriers that have 
been proven to be non-inflammatory and non-toxic while enabling the delivery of highly 
localized concentrations of both hydrophilic and hydrophobic agents 103-105. In particular, 
polymer nanoparticle-based drug delivery systems have been evaluated as attractive options for 
efficacious delivery of agents such as drugs and genes with resulting treatment efficacy 104,105. 
The pharmacokinetics of polymeric systems can be tailored by changing the polymer monomer 
concentrations to facilitate agent diffusive transport, typically via a combination of burst and 
sustained release profiles.  
Besides enabling the sustained release of encapsulated agents, relative to systemic options, local 
intravaginal therapy may represent a relatively non-invasive approach to locally treat cervical 
tumors 100.  Nanoparticles (NP) can be modified to minimize unwanted systemic interactions, 
prolong bioavailability, promote targeted delivery to the physiologic site of interest, and enhance 
tumor penetration and cellular uptake 106. Different types of NP surface modifications can be 
utilized to elicit these desired behaviors. Stealth coatings such as polyethylene glycol (PEG) can 
decrease unwanted systemic interactions and neutralize the carrier’s surface charge 107,108, while 
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targeting ligands can increase the specificity of conjugated carriers to systemically target the 
desired physiological environment 109. Cell penetrating peptides, such as MPG, RGD, and Tat1, 
are examples of short ligands that can enhance the cellular internalization of their conjugated 
carriers 55,110-120. In particular, previous studies have shown that NP surface modification  with 
the amphipathic, synthetic peptide MPG derived from HIV gp41 and SV40 115,121 displays high 
cellular binding and internalization achieved via clathrin-mediated endocytotic uptake28.  
 
Tumor tissue is typically characterized by an overabundance of extracellular matrix as well as 
poorly vascularized areas, both of which can hinder diffusive transport of NPs 103.  Thus, in 
addition to evaluating cellular uptake capability, delivery systems would benefit from testing in a 
three-dimensional (3D) environment which more closely represents hypo-vascularized tumor 
lesions. For this purpose, 3D cell culture provides a suitable platform 122,123 that is more 
controllable than tumors in vivo. Previously, 3D cell culture has been employed to study the 
behavior of various nano-carriers, such as gold and polymeric NPs. It has been shown both  
experimentally 48,124-127 and theoretically 49,51,52,61,128-133 that NPs require appropriate 
characteristics and surface modifications to adequately penetrate hypo-vascularized regions for 
effective therapeutic delivery, even if cellular internalization is optimized.  
 
With the goal to enhance both the transport and internalization of therapeutic agents in hypo-
vascularized tumor tissue, in this study we evaluate a variety of poly(lactic-co-glycolic) acid 
(PLGA) NP formulations for tissue penetration and cellular internalization. The NPs were 
modified with either a cell penetrating peptide (MPG), a stealth ligand (PEG), a tumor targeting 
cell penetrating peptide (Vimentin tubulin binding site peptide, VIM) 134,135,  or a hybrid 
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modification with both cell penetrating peptides and stealth ligands (MPG/PEG). These ligands 
were chosen because they have already been individually well characterized to enhance cell 
internalization, e.g., as we have previously shown for MPG. We assess how the NP surface 
modifications affect uptake in cervical tumor cells, and compare the NP performance in normal 
vaginal cells. We further evaluate the NP transport and internalization in a 3D spheroid model 
representing hypo-vascularized cervical cancer lesions. 
 
B. METHODS 
Synthesis of avidin-palmitate conjugates 
Avidin-palmitate was conjugated to NP surfaces as previously described39,136 for subsequent 
reaction with biotinylated ligands: MPG, PEG, VIM, and an equimolar combination of 
MPG/PEG. Briefly, 40 mg of avidin was dissolved in 4.8 mL of 2 % sodium deoxycholate 
(NaDC) in phosphate buffered saline (PBS) warmed to 37 °C. Palmitic acid-N- 
hydroxysuccinimide ester (PA-NHS, Sigma) was dissolved in 2 % NaDC at 1 mg/mL and 
sonicated until well-mixed. 3.2 mL of the 1 mg/mL PA-NHS solution was added dropwise to the 
reaction vial, and reacted overnight at 37 °C. The following day, the reaction was dialyzed 
overnight in 1200 mL of 0.15 % NaDC in PBS heated to 37 °C. Free PA-NHS was removed 
using 3500 molecular weight cut off (MWCO) dialysis tubing, and the dialysis cassette contents 
were subsequently transferred to a vial and stored at 4 °C. 
Nanoparticle synthesis 
We synthesized and characterized PLGA NPs encapsulating a fluorescent dye, Coumarin 6 (C6), 
to evaluate tumor penetration and distribution via fluorescence microscopy. From earlier 
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studies33,137-139 as well as our previous experiments, we have observed that negligible quantities 
(~1 %) of C6 are released from NPs. This is attributed to the hydrophobic nature of C6 
encapsulated within hydrophobic NPs. Therefore, C6 detected in cells reflects NP distribution in 
or on the cells, not C6 release and distribution. C6 NPs were synthesized as previously described 
using an oil-in-water (o/w) single emulsion technique39. Briefly, C6 was encapsulated into 100-
200 mg PLGA carboxyl-terminated polymer (0.55–0.75 dL/g, LACTEL®). C6 was dissolved in 
methylene chloride (DCM) overnight at a concentration of 15 μg C6 per mg of PLGA. The 
following day, the solution was added dropwise to a 5 % polyvinyl alcohol (PVA) solution of 
equal volume, vortexed and sonicated. The resulting NPs were hardened during solvent 
evaporation for 3 h. For unmodified NPs, the NPs were washed after hardening, and centrifuged 
3 times at 4 °C in deionized water (diH2O) to remove residual solvent. For avidin-palmitate 
surface-modified NPs, a similar protocol was followed39,137.  NP formulations were synthesized 
by adding (1 mg/mL) avidin-palmitate to the 5 % PVA solution. NPs were collected after the 
first wash and incubated for 30 min with biotinylated ligands at a molar ratio of 3:1 ligand:avidin 
in PBS. After conjugation, the NPs were washed two more times with diH2O by centrifugation 
and subsequent washing. All NPs were frozen, lyophilized, and stored at −20 °C until use. 
Cell culture 
VK2/E6E7 vaginal epithelial (VK2) and human cervical carcinoma (HeLa) immortalized cell 
lines were kindly provided by Dr. Kenneth Palmer’s lab (University of Louisville). These cell 
lines were obtained and authenticated through ATCC. We selected the VK2/E6E7 cell line, since 
for intravaginal delivery these would be the first “normal” cells to encounter NP treatment. HeLa 
cells provide the ability to assess NP behavior against a cervical cancer cell line in vitro. 
VK2/E6E7 vaginal epithelial cells (VK2) were maintained in Defined Kerotinocyte-Serum Free 
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medium (SFM) supplemented with Defined Keratinocyte-SFM Growth Supplement. HeLa cells 
were maintained in minimal essential media (MEM) supplemented with 10 % fetal bovine serum 
and 1 % penicillin–streptomycin in standard culture conditions. Cell media was checked and 
changed daily. 
Tumor spheroid formation 
HeLa cells were used for tumor spheroid formation. Cells were grown to 80 % confluence before 
harvesting. Twenty-four well tissue culture plates (Corning) were coated with a 1 % (w/v) 
agarose gel 24 h before spheroid formation to prevent cell adherence. For formation, 100,000 
cells were placed in each well and lightly shaken (100 rpm) for 15 min on a reciprocating shaker. 
After 7–14 days of incubation, spheroid formation occurred by self-aggregation to sizes ranging 
from 500 to 1000 μm. 
Monolayer (2D) cellular uptake and microscopy 
2D cellular imaging of 1.5 and 24 h NP uptake and penetration in HeLa and VK2 cells was 
performed via inverted epifluorescence microscopy. VK2 and HeLa cells were seeded 24 h prior 
to NP administration in LabTek 8-well chamber slides at a density of 50,000 and 40,000 cells per 
well for 1.5 and 24 h uptake, respectively. For NP administration, NPs were massed out and 
dissolved to reach a final stock concentration of 0.6 mg/mL in PBS++ (containing CaCl2 and 
MgCl2) to aid cell adherence. One hundred microliters of fresh media were added to the cells, 
and NPs were then added to obtain a final NP concentration of 200 μg/mL. 
After either 1.5 or 24 h incubation, cells were washed five times in 0.5 mL of 1X PBS to remove 
any unbound or non-internalized NPs. Cells were then fixed with 0.3 mL of 4 % 
paraformaldehyde and incubated for 10 min at room temperature (RT). Cells were subsequently 
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washed twice with 0.5 mL of PBS and permeabilized with 0.3 mL of 0.1 % Triton X-100 in 1 % 
bovine serum albumin (BSA) PBS++ for 10 min at RT. After permeabilization, cells were 
incubated with 0.3 mL of 1:40 Texas Red Phalloidin in 1 % BSA PBS++ for 20 min at RT for 
cytoskeleton staining and were subsequently washed twice with 0.5 mL PBS. Cells were then 
incubated with 0.3 mL of 4 μg/mL Hoechst in 1 % BSA PBS++ for 10 min at 37 °C for nuclear 
staining. Finally, cells were washed twice in PBS and once in diH2O, then mounted in 
Vectashield non-hardening mounting medium (Vector Laboratories, VWR) and kept at 4 °C until 
imaged. 
Inverted epifluorescence microscopy was utilized to assess cellular uptake of NPs in 2D 
monolayers. Briefly, cells were prepared as described above and imaged in 8-well LabTek 
chamber slides using the following filter settings: 4′,6-diamidino-2-phenylindole (DAPI) to 
visualize Hoechst, green fluorescent protein (GFP) for C6, and the Texas Red channel to 
evaluate NP uptake in 2D. Exposure times for DAPI, GFP, and Texas Red were kept consistent 
throughout experiments and were as follows: DAPI at 45 ms (excitation/emissions: 358/461 nm); 
GFP at 60 ms (593/615 nm); and Texas Red at 180 ms (488/515 nm). 
Spheroid (3D) cellular uptake and microscopy 
To assess the differences in NP uptake and distribution through hypo-vascularized tumor tissue, 
HeLa spheroids were incubated with 0.01 mg/mL of NPs and visualized using confocal 
microscopy. Diffusion profiles through the spheroids for each NP formulation were evaluated by 
quantifying the fluorescence intensity in z-stack images as a function of distance from the 
spheroid periphery. After NP administration, tumor spheroids were transferred to LabTek 8-well 
chamber slides for fluorescent staining and were washed five times with 0.2 mL 1X PBS. Tumor 
spheroids were subsequently incubated for 10 min at RT with 0.2 mL 4 % paraformaldehyde for 
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spheroid fixation. Following fixation, spheroids were washed twice with 0.2 mL of PBS, 
followed by incubation with 0.2 mL of 1:40 Texas Red Phalloidin in 1 % BSA PBS++ for 20 
min at RT for cytoskeleton staining. Spheroids were then washed twice with 0.2 mL PBS and 
incubated with 0.2 mL of 4 μg/mL Hoechst in 1 % BSA PBS++ for 10 min at 37 °C for nuclear 
staining. Finally, spheroids were washed twice in 0.2 mL PBS and once in 0.2 mL diH2O. 
Spheroids were then mounted with Vectashield non-hardening mounting medium. 3D uptake and 
distribution of NPs through tumor spheroids was assessed using confocal microscopy. Images 
were processed using ImageJ by taking representative samples from tumor cross-sections (≥90 
averaged profiles for each sample). 
Flow cytometry analysis 
Cells were plated in 6-well plates (Corning) at a density of 200,000 cells per well. Both VK2 and 
HeLa cell lines were incubated with NP suspensions at 0.05 mg/mL for either 1.5 or 24 h in a 37 
°C humidified chamber in the appropriate medium. An unmodified NP control group was used to 
compare uptake relative to surface-modified NPs, as our previous work demonstrated minimal 
difference between unmodified and avidin-modified NP association and uptake. After 
incubation, the cells were washed five times with PBS++. Next, the cells were dissociated with 
enzyme-free cell dissociation buffer (ThermoFisher). The dissociated cells were moved to FACS 
tubes, centrifuged, and resuspended in a FACS buffer solution containing 1 % BSA and 0.1 % 
sodium azide. From each sample, half the cells were moved to separate FACS tubes and kept on 
ice until analyzed (total associated samples). The remaining cells were exposed to 0.4 % trypan 
blue for 5 min to quench extracellular fluorescence, washed twice in FACS buffer, and kept on 
ice until analyzed (internalized samples) . All FACS tubes from both groups were analyzed using 
a BD LSRFortessa Flow Cytometer (BD Biosciences). Data were analyzed using FlowJo 
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software (FlowJo Enterprise), and a minimum of 10,000 cells were analyzed per sample. For 
flow cytometry analysis of tumor spheroids, a similar protocol was followed using spheroids 
after 7 days of growth. Instead of enzyme-free cell dissociation buffer, 0.25 % Trypsin–EDTA 
was used to fully disaggregate the spheroids before centrifugation and resuspension in FACS 
buffer solution. 
Statistical analysis 
Experiments were conducted each with a minimum sample size of n = 3. Data were analyzed by 
applying Tukey’s test with significance p < 0.05. Unless otherwise noted, all figure error bars 
represent the standard deviation of the measurements. To enable clear interpretation, statistically 
similar results are shown linked with an overbar in the figures of the “Results” section. 
 
C. RESULTS 
Nanoparticle characterization 
The NP surface was first modified with avidin-palmitate, and different NP groups were created 
based on the addition of one of the following biotinylated ligands: MPG, MPG/PEG, PEG, or 
VIM, as described in the “Methods” section. Figure 1 illustrates the NPs used in this study. The 
average unhydrated NP diameter measured 167 ± 50 nm. Hydrodynamic sizes and surface 
charges for the different NP groups were quantified via dynamic light scattering (DLS) and zeta 
potential measurements, respectively (data not shown). 
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Figure 1. Schematic illustrating NP formulations used in this study 
Unmodified NPs had a hydrodynamic diameter of 267 ± 13.6 nm and a negative surface charge 
of −17.3 ± 0.5 mV, and the addition of avidin-palmitate increased this surface charge to −14.3 ± 
0.59 mV. The surface charge was further increased with the addition of the ligands, with MPG-
modified NPs having the most positive charge at −0.4 ± 0.2 mV, followed by PEG and 
MPG/PEG with −5.2 ± 1.3 and −5.3 ± 0.7 mV, respectively, and VIM with −11.1 ± 1.0 mV. NP 
hydrodynamic sizes ranged from 232 to 277 nm for both unmodified and surface-modified 
groups, with no statistically significant difference between the groups. 
 
Uptake of PLGA-modified nanoparticles in cervical cancer cell monolayers 
Cellular association (binding plus internalization) and internalization in 2D cell culture 
monolayers were quantitatively assessed using Fluorescence Activated Cell Sorting (FACS) with 
cervical tumor epithelial cells (HeLa) and normal vaginal epithelial cells (VK2) (Fig. 2). Both 
HeLa and VK2 cells were incubated with the same concentration of NPs (0.05 mg/mL) for 1.5 or 
24 h, regardless of modification. For HeLa cells, all of the modified NP groups showed both 
greater total association as well as internalization relative to unmodified NPs at both time points. 
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At 1.5 h, MPG, MPG/PEG, PEG, and VIM NPs were internalized at 607×, 184×, 79×, and 57× 
that of unmodified NPs, respectively (Fig. 2a). Comparing the formulations to each other, the 
MPG NPs showed 3.3×, 7.6×, and 10.5× greater internalization than the MPG/PEG, PEG, and 
VIM NPs, respectively. After 24 h of incubation, MPG, MPG/PEG, PEG, and VIM NPs were 
internalized at 66×, 24×, 30×, and 15× that of unmodified NPs, respectively (Fig. 2b). The MPG 
NPs were internalized at 2.7×, 2.2×, and 4.5× that of MPG/PEG, PEG, and VIM NPs, 
respectively. Since the internalization for the MPG NPs was essentially the same at both time 
points, these data highlight the increase in internalization of the other formulations after longer 
exposure times. 
 
Uptake of PLGA-modified nanoparticles in vaginal epithelial cell monolayers 
In contrast, NP association with VK2 cells at 1.5 h was not as distinct between the various 
modified formulations (Fig. 2c), whereas PEG NPs internalized at 2.1×, 5.9×, and 8.8× 
compared to MPG, MPG/PEG and VIM NPs, respectively. Comparing to unmodified NPs, the 
MPG, MPG/PEG, PEG, and VIM NPs internalized respectively at 20×, 7×, 43×, and 5×. After 
24 h however, a clearer separation in association was apparent and PEG NPs were internalized at 
1.9×, 2.8×, and 4.0× compared to MPG, MPG/PEG, and VIM NPs, respectively (Fig. 2d). 
The internalization remained invariant when comparing MPG and PEG between the two time 
points, while the internalization of MPG/PEG and VIM essentially doubled. When compared to 
unmodified NPs after 24 h incubation, the MPG, MPG/PEG, PEG, and VIM internalized at 6.3×, 
4.3×, 12.4×, and 3.0× that of unmodified NPs. 
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Figure 2. Cellular association and internalization of the various NP formulations are presented 
for HeLa (top) and VK2 (bottom) cells, shown at 1.5 h (left) and 24 h (right). Statistically similar 
results are shown linked with an overbar 
Comparison of nanoparticle uptake between tumorigenic and normal cell monolayers 
Of note after 24 h, the unmodified NPs readily associate with the VK2 cells, in contrast to HeLa 
cells; however, unmodified NPs demonstrate low levels of internalization in both cell lines. In 
contrast, surface-modified NP uptake was significantly enhanced in both the HeLa and VK2 cell 
lines. MPG NPs were internalized the most in HeLa cells; whereas PEG NPs were internalized 
most highly in VK2 cells. While both surface-modified groups (MPG and PEG) demonstrated 
strong internalization in HeLa and VK2 cells respectively, MPG was internalized in HeLa cells 
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2× that of the PEG NPs by the VK2 cells. When comparing between the earlier and later time 
points, it is apparent that the PEG NPs showed the highest increase in both association and 
internalization by the longer exposure with the tumorigenic HeLa but not with the normal VK2 
cells. Cellular association and internalization were qualitatively assessed via inverted 
epifluorescence microscopy for both HeLa and VK2 cells at 1.5 h (data not shown) and 24 h 
incubation times (Figs. 3, 4). Although the images for the most part reflect the flow cytometry 
results in Fig. IV, they are representative samples providing a limited assessment. 
 
Figure 3. Total NP association (binding and internalization) in monolayers of HeLa cells after 
24 h incubation. Nuclei are blue (Hoechst), actin cytoskeletons are red (Texas red phalloidin), 
and NPs are green (Coumarin 6). Bar 50 μm 
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Figure 4. Total NP association (binding and internalization) in monolayers of VK2 cells after 24 
h incubation. Nuclei are blue (Hoechst), actin cytoskeletons are red (Texas red phalloidin), and 
NPs are green (Coumarin 6). Bar 50 μm 
Uptake of PLGA-modified nanoparticles in hypo-vascularized cancer lesions 
Cellular association and internalization in 3D cell culture (HeLa cervical tumor spheroids), 
incubated with the same concentration of NPs (0.05 mg/mL) as the monolayers, were 
quantitatively assessed at 1.5 and 24 h via flow cytometry (Fig. V5). At 1.5 h, as a group, all of 
the modified NPs had higher association than the unmodified NPs, with statistically similar 
association when compared to each other. The surface-modified NPs also evinced a statistically 
similar internalization when compared to each other, but in this case, as a group the MPG, 
MPG/PEG, and VIM NPs showed higher internalization than the unmodified and PEG NPs (Fig. 
5a). In contrast, after 24 h, the unmodified and surface-modified NPs (except for VIM, which 
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was lower) showed statistically similar association (Fig. 5b), while MPG and MPG/PEG showed 
2× and 3× internalization relative to PEG and VIM NPs, respectively. Interestingly, unlike the 
results obtained with the monolayer, in the 3D cell culture the association of all NPs increased 
significantly at 24 h compared to the 1.5 h time point: unmodified by 4.8×, MPG by 2.6×, 
MPG/PEG by 3.0×, PEG by 1.6×, and VIM by 1.6×. Internalization also increased at the later 
time point, with MPG and MPG/PEG NPs being internalized the most (at 3.6× and 3.8× 
compared to 1.5 h, respectively), while VIM or unmodified versions were internalized the least. 
 
Figure 5. Cellular association and internalization of the various NP formulations in HeLa cell 
tumor spheroids. Results are shown at (a) 1.5 and (b) 24 h. Statistically similar results are shown 
linked with an overbar 
Comparison of nanoparticle uptake between 2D and 3D cell cultures 
In general, all of the values measured from 3D cell cultures were lower than those from the 2D 
cell cultures, highlighting the effect of the diffusive transport barrier in hypo-vascularized tissue. 
Figure 6 summarizes the NP cellular internalization as a function of surface modification, cell 
culture type, and treatment duration, highlighting the effect of diffusive transport on NP uptake 
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between the monolayer and tumor environments. It is expected that monolayer culture represents 
optimal conditions in terms of diffusive transport, and therefore association and internalization 
would be lower in the 3D tumor environment. 
 
Figure 6. Comparison of NP cellular internalization between HeLa monolayer and spheroid cell 
cultures. Results are shown at (a) 1.5 and (b) 24 h 
Transport of PLGA-modified nanoparticles in hypo-vascularized cancer lesions 
The NP diffusion profiles after 1.5 h through the spheroid tissue are presented in Fig. 7, showing 
that MPG and PEG-modified NPs exhibited the greatest fluorescence intensity averaged over 
200 × 80 μm areas, followed by MPG/PEG and VIM NPs. In particular, MPG NPs were heavily 
detected in the periphery (within 100 μm of the edge) of the spheroids, viz., 2×, 1.4×, and 2.7× 
that of PEG, MPG/PEG, and VIM NPs, respectively, while PEG NPs penetrated 2× farther (250 
μm) into the spheroid than the MPG NPs. In comparison, unmodified NPs exhibited the lowest 
detection and penetration into the tumor spheroids. 
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Figure 7. NP penetration into 3D cell culture (HeLa spheroids) after 1.5hr incubation. 
 
D. DISCUSSION 
Building upon our previous work using avidin-palmitate PLGA NPs with modified surface 
chemistry, here we study the effects of contrasting and hybrid surface modifications on NP 
transport and cellular internalization in cervical tumor cells. Previously, avidin-palmitate NPs 
conjugated with the cell-penetrating peptide MPG were shown to have rapid internalization in 
monolayer cervical carcinoma (HeLa) cells, with a significant improvement over unmodified 
NPs. Here, we expand the suite of NP surface modifications to include PEG, VIM, and a hybrid 
modification of MPG and PEG. These formulations were evaluated for their internalization over 
short and extended time periods (1.5 and 24 h, respectively) in monolayer cell culture, 
representing optimal transport conditions, and in tumor spheroid cultures, representing hypo-
vascularized tumor lesions with diffusive transport limitations. Additionally, we extend our 
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analysis beyond cancerous cells to include normal vaginal cells (VK2) to assess potential 
differences in the efficacy of different surface modifications when targeting tumor versus non-
tumor cells present in the female reproductive tract. 
The NP formulations were characterized using standard methods to evaluate size, hydrodynamic 
size, and zeta potential. Unmodified NPs exhibited the most negative surface charge, while 
surface modification increased the surface potential to more positive values. MPG NPs exhibited 
the greatest increase in surface potential, as MPG is an amphipathic peptide that contains a 
cationic sequence known to enhance cell surface interaction. All NP surface modifications 
yielded an improvement in cellular association and internalization over unmodified NPs under 
optimal transport conditions in HeLa monolayer cell culture (Fig. 3a, b). MPG-modified NPs had 
the highest cellular association and internalization at both 1.5 and 24 h, indicating their potential 
to efficaciously promote NP uptake. The hybrid MPG/PEG NPs showed significantly enhanced 
uptake at 1.5 h, greater than both PEG and VIM-modified NPs. However, PEG significantly 
increased cellular internalization after a longer exposure time and surpassed the hybrid 
MPG/PEG NPs. The MPG, VIM, and hybrid NPs showed modest improvement in internalization 
after longer treatment duration. These results are in agreement with our previous work that 
MPG-modified NPs have a rapid mechanism of uptake in HeLa cells while PEG-modified NPs 
take longer to internalize. This is consistent with PEG functionality, which is designed to prolong 
half-life in vivo. 
In contrast, in normal vaginal cells (VK2), PEG-modified NPs exhibited similar high uptake and 
internalization at 1.5 and 24 h (Fig. 4c, d), while MPG and MPG/PEG NPs showed only slight 
internalization. In fact, the MPG-modified NPs demonstrated greater than threefold improvement 
in internalization by cancerous relative to normal cells. These results suggest that the association 
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and uptake of these NPs in normal cells may be mediated by different molecular mechanisms or 
cell surface moieties than in cancerous cells, which may have significant implications in more 
specific targeting of cancer lesions. The results further suggest that while VIM NPs are more 
efficacious than unmodified NPs, VIM most likely does not serve a specific targeting purpose for 
these cells. Enhancement is most likely due to the slightly more positive surface potential 
compared to that of the unmodified NPs. The high internalization of PEG-coated NPs in the VK2 
cells, and also after 24 h in HeLa cells, indicates that these NPs might provide a means to 
enhance transport and concentration of therapeutics into normal vaginal tissue, while also 
offering the potential for enhanced uptake in cancerous cells. 
Following the assessment of cellular internalization in optimally diffusive (monolayer) 
conditions, a similar evaluation was performed in 3D cell culture of HeLa cells to assess the 
transport and uptake of these NPs in hypo-vascularized tumor tissue. After the short incubation 
of 1.5 h, all surface-modified NPs performed similarly (Fig. 5), demonstrating slightly increased 
internalization relative to the unmodified NPs. After 24 h, the MPG and MPG/PEG NPs 
exhibited the most internalization relative to the other NP groups. Unlike the monolayer cultures, 
none of the groups saturated the spheroids at 1.5 h, and instead elicited a more gradual, yet 
significant increase in internalization with longer exposure time. These results highlight the 
diffusive transport limitation through the 3D tissue culture as a time-dependent process, and 
enable a more detailed assessment of NP performance. The transport limitation in 3D tissue is 
well known (e.g., 140-144), and derives from the extra-cellular matrix as well as cell–matrix and 
cell–cell interactions (such as E-cadherin) impeding diffusive flow145,146. Whereas in monolayer 
HeLa and VK2 cell cultures the MPG and PEG NPs were internalized the most compared to the 
other groups, in the 3D cell culture the MPG and MPG/PEG NPs showed highest internalization. 
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The diffusive transport limitation is further emphasized in Fig. 5, which compares the 2D and 3D 
internalization of the NPs in monolayer versus spheroid cultures. 
As shown in Fig. 7, PEG NPs have the greatest depth of penetration into the spheroid tissue, with 
maximal concentration reached at 125 μm. In contrast, the MPG NPs achieved the highest 
concentration along the tumor periphery (maximally at 65 μm), but were unable to fully 
penetrate it. As shown in the monolayer, MPG NPs have the highest rate of cellular 
internalization, which is critical to the success of some biological therapeutics that cannot 
transverse cellular membranes alone, such as oligonucleotides, but this increased internalization 
may limit the depth of penetration. In contrast, the PEG modification, being very hydrophilic and 
less positively charged, enables NPs to more easily navigate the extracellular space and penetrate 
deeper into the spheroid tissue at the expense of internalization. 
In living subjects, circulating NPs can preferentially lodge in tumor tissue by extravasating from 
fenestrated capillaries 147 as a result of the enhanced permeability and retention effect (EPR).  
Nevertheless, it has been shown that NP diffusive transport only extends about 30-50 μm away 
from the vessels 148,149. Consequently, therapeutics released from these NPs may not attain 
cytotoxic concentrations and also fail to affect quiescent (non-cycling) cells in regions distal to 
the vasculature 150.  Previously, we evaluated drug and NP transport in 2D and 3D cell culture, 
showing that nanoparticles layered with combinations of hexadecanethiol, phosphatidylcholine 
and high-density lipoprotein diffused deeper than PEGylated NPs into 3D cell culture  
representing hypo-vascularized tissue 151.  The NPs were uptaken in solid tumor tissue in vivo 152, 
and elicited distinctive drug release kinetics when loaded with paclitaxel or cisplatin 153.  
Cytotoxicity experiments with free drug showed a substantial differential between 2D and 3D 
cell cultures, highlighting the increased resistance due to diffusive transport 124, although the 
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drug-loaded layered NPs were substantially more efficacious in 3D cell culture than free-drug.  
While these findings are consistent with previous work showing decreased efficacy in 3D cell 
culture compared to monolayer 122,148, they offer hope that modification of NPs to enhance their 
uptake and transport in cancerous tissue can help overcome the limitations of diffusive transport. 
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III. Distribution of PLGA-modified nanoparticles in 3D cell culture models of hypo-vascularized 
tumor tissue 
 
 
Adapted From: 
Sims LB, Huss M, Frieboes H, Steinbach-Rankins JM; Distribution and Uptake of PLGA-modified Nanoparticles to 
Target Heterogeneously Vascularized Cervical Cancer Lesions; October 5, 2017; Journal of Nanobiotechnology1 
 
 
A. CLINICAL SIGNIFICANCE AND BACKGROUND 
Relative to effective and non-invasive preventative options such as vaccines, late-stage cancer 
treatments are usually invasive and painful, and typically include surgery, chemotherapy, and 
radiation treatment. Chemotherapy often induces irreversible damage to surrounding healthy 
tissue as well as incomplete tumor eradication. For systemic chemotherapy specifically, it can be 
challenging to achieve distribution throughout the tumor to maximize treatment effectiveness. 
Nanotherapeutic platforms have been proposed as safer and more effective modalities to deliver 
therapeutic agents directly to the tumor site. In particular, FDA-approved polymer-based 
platforms such as poly(lactic-co-glycolic) acid (PLGA) NPs, have been utilized to reduce 
unwanted immunogenic responses. Although NPs have been surface-modified with a variety of 
ligands to enhance tumor penetration and targeting 8,17,28,29,115,154-158, currently, two delivery 
paradigms exist, often with cellular internalization and tissue penetration diametrically opposed. 
In trying to achieve enhanced cellular internalization, the efficacy benefit may be limited if 
surface-modification prevents the carrier from penetrating deeply into the tumor interstitium28. 
Conversely, if penetration into the tumor interstitium is successfully achieved – thereby 
providing broad distribution throughout the tumor – delivery vehicles may be inadequately 
internalized by the cells targeted. Unfortunately, similar ineffective therapy results in both cases.  
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To balance these transport challenges, NPs are often surface-modified with ligands to enhance 
transport and longevity after localized or systemic administration.  One of the most common 
ligands used to functionalize and promote NP delivery, poly(ethylene-glycol) (PEG), has been 
employed as a “stealth” modification, due to its hydrophilic and easily tailorable properties. PEG 
has been shown to increase vehicle circulation time by decreasing unwanted systemic 
interactions, and has enhanced transport through interstitial space and intercellular junctions 
2,13,29,30,75,79,151,159-161. In contrast, cell penetrating peptides (CPPs) – short amphipathic or 
polycationic peptides − have been utilized to improve the intracellular delivery of cargo. Due to 
their cationic and sometimes lipophilic properties, CPPs have been designed to promote the 
internalization of attached cargo across cell membranes, particularly for gene delivery 
applications 28,115,154,155,158,160,162.  
For cervical cancer specific applications, a variety of polymeric NP formulations have been 
recently investigated to deliver chemotherapeutics. Nanoparticle derivatives of PLGA 157,163-165 
have demonstrated sustained delivery of docetaxel against cervical cancer both in vitro and in 
vivo, correlated with high uptake and corresponding antitumor effects. Similarly, Eudragit-E and 
polyvinyl alcohol NPs containing Naringenin induced dose-dependent cytotoxicity 166. In another 
study, genistein-encapsulated ε-caprolactone-based NPs demonstrated enhanced cytotoxicity and 
growth inhibition in a  murine HeLa xenograft tumor model 167. Folate-targeted doxorubicin-
loaded NPs have improved targeting and anti-tumor efficacy in vivo 161 and pullulan acetate 
folate-modified NPs were used to treat cervical carcinoma 167. Peng et al. utilized a 
thermosensitive gel to target DNA poly(β-amino ester) NPs to ex vivo pre-neoplastic cervical 
lesions and mouse cervical tissue 168. Similarly, Blum et al. developed topical camptothecin-
loaded PLGA nanoparticles to prevent tumor growth in an inducible murine model of vaginal 
63 
 
squamous cell carcinoma 169. Most recently, Yang et al. evaluated paclitaxel mucus penetrating 
or adhesive PLGA NPs, demonstrating significantly less tumor growth and increased survival 
with mucoadhesive NPs 35.  
Previously, we investigated the effects of NP surface-modification with cell-penetrating peptides 
(CPPs), stealth ligands, and tumor targeting ligands (MPG (unabbreviated notation), PEG, and 
Vimentin, respectively), on NP penetration and distribution within the hypo-vascularized tumor 
environment 2. Nanoparticles modified with a CPP, MPG, exhibited the highest cellular 
internalization in human cervical carcinoma (HeLa) 3D cell culture (multi-cellular spheroids); 
however, internalization primarily occurred within the spheroid periphery, resulting in a modest 
(< 100 nm) distribution profile. In contrast, PEG-modified NPs distributed more deeply into 
spheroids, but were less readily internalized by cells. These results seemed to indicate that tissue 
morphology in addition to NP functionalization were key factors determining NP distribution. 
In this study, we consider tissue morphology while evaluating the penetration and distribution of 
PEG, cell penetrating (MPG), and CPP-stealth (MPG/PEG) NP co-treatment strategies in models 
of hypo-vascularized cervical cancer tissue representing regions distal from the point of vascular 
extravasation (Fig. 1).  To model more regularly-shaped tissue, we utilized the hanging drop 
(HD) method to generate smaller, more homogeneously spherically-shaped spheroids. We 
compared NP penetration to that in tissue formed via the liquid overlay (LO) technique, in which 
spheroids form more irregularly-shaped masses. To compare differences in NP distribution 
within the same type of lesion but as a function of different cervical cancer types, we selected 
HeLa, cervical epithelial adenocarcinoma cells; CaSki, cervical epidermoid carcinoma cells; and 
SiHa, grade II cervical squamous cell carcinoma cells. Thus, the goal was to assess differences in 
NP distribution as a function of NP surface-modification (unmodified, MPG, PEG, or MPG/PEG 
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NP co-treatment), hypo-vascularized tissue (regular or irregular morphology), and cancer cell 
type. 
B. METHODS 
Synthesis of avidin-palmitate conjugates 
Avidin-palmitate was synthesized for subsequent conjugation to NPs as previously described2,136. 
Briefly, 40 mg of avidin (A9275, Sigma) was dissolved in 4.8 mL of 2% sodium deoxycholate 
(NaDC) in phosphate buffered saline (PBS) warmed to 37 °C. Palmitic acid-NHS (PA-NHS, 
Sigma) was dissolved in 2% NaDC to a final concentration of 1 mg/mL and sonicated until well-
mixed. PA-NHS solution (3.2 mL) was added dropwise to the avidin NaDC solution, and reacted 
overnight at 37 °C. The following day, the reaction was dialyzed in 1200 mL of 0.15% NaDC in 
PBS heated to 37 °C. Free PA-NHS was dialyzed overnight at 37 °C using 3500 MWCO tubing 
to remove free palmitic acid. After overnight dialysis, the dialysis tubing contents were 
transferred to a storage vial and stored at 4 °C until use. 
Nanoparticle synthesis 
PLGA NPs encapsulating the fluorophore Coumarin 6 (C6) were synthesized as previously 
described 2,39 to enable visualization via fluorescence microscopy. From earlier studies 33,137-139, 
as well as our previous experiments 2,28, we have observed that negligible quantities (~1 %) of 
C6 are released from NPs. This is attributed to the hydrophobic nature of C6 encapsulated within 
hydrophobic NPs. Therefore, C6 detected in cells reflects NP distribution in or bound to the 
cells, not C6 release and distribution.  Briefly, C6 NPs were synthesized using an oil-in-water 
(o/w) single emulsion technique 2,13,39. Carboxyl-terminated poly(lactic co-glycolic acid, PLGA) 
(0.55-0.75 dL/g, LACTEL®) was used to synthesize 100-200 mg batches. Coumarin 6 was 
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dissolved in methylene chloride (DCM) overnight at a concentration of 15 μg C6 per mg of 
PLGA. The following day, the PLGA/C6/DCM solution was added dropwise to a 5% polyvinyl 
alcohol (PVA) solution of equal volume, vortexed and sonicated. The resulting NPs were 
hardened in 0.3% PVA during solvent evaporation for 3 hr. 
Unmodified NPs were washed after hardening, and centrifuged at 4 °C, 3 times in deionized 
water (diH2O) to remove residual solvent. NPs were frozen, lyophilized, and stored at − 20 °C 
until use. A similar protocol was followed to synthesize MPG (3177 Da, GenScript) and PEG 
(5000 Da, Nanocs Inc.) modified NPs, with the addition of avidin-palmitate (1 mg/mL) to the 5% 
PVA solution. Surface-modified NPs were collected after the first wash, and incubated for 30 
min with biotinylated ligands at a molar ratio of 3:1 ligand:avidin in PBS. After the conjugation 
reaction, the NPs were washed two more times with diH2O centrifugation, frozen, and 
lyophilized. All NPs were stored at − 20 °C after synthesis. 
Nanoparticle characterization 
NP characterization confirmed physical properties including NP diameter, morphology, and 
surface charge. First, scanning electron microscopy (SEM, Zeiss SUPRA 35VP) was utilized to 
verify NP morphology. Unhydrated NP diameters were measured using NIH ImageJ software. 
NP surface charges were characterized using a Malvern Zetasizer (Zetasizer Nano ZS90). 
Three-dimensional cell cultures 
The human cervical carcinoma cell lines, SiHa, and CaSki (ATCC), were kindly provided by Dr. 
Alfred Jenson (University of Louisville), while the HeLa cell line was generously provided by 
Dr. Kenneth Palmer (University of Louisville). HeLa and SiHa cells were maintained in 
Minimum Essential Media (MEM) and CaSki cells were maintained in RPMI medium, both 
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supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin. All cells were kept 
in a humidified atmosphere of 5% CO2 at 37 °C, and were grown to 80% confluence prior to 
tumor spheroid formation. 
Liquid overlay tumor spheroid formation 
Liquid overlay spheroids were grown as previously described2,50.. Briefly, to prevent spheroid 
adherence to the plate, 24-well tissue culture plates (#353047, Corning) were coated with a 1% 
(w/v) agarose gel 6 h prior to spheroid formation. After trypsinization, cells were collected and 
plated at a density of 100,000 cells per well containing 700 μL culture medium and lightly 
shaken (100 rpm) for 15 min on a reciprocating shaker. Following this, culture plates were 
transferred to an incubator and maintained at 37 °C and 5% CO2. Spheroids were grown for 7 
days with culture media changes every 2 days (Fig. 1). 
Hanging drop tumor spheroid formation 
To form hanging drop spheroids, ultra-low attachment plates (#4515, Corning) were utilized. 
Briefly, cells were trypsinized after reaching 80–90% confluency and seeded at a density of 5000 
cells per well in 100 μL culture medium. Care was taken to minimize pipette tip contact with 
ultra-low attachment plate well walls. Spheroids were allowed to form for 5 days under the cell 
culture conditions described above (Fig. 1). 
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Figure 1. Schematic of spheroid formation techniques for a liquid overlay (LO) and b hanging 
drop (HD) spheroids, respectively representing larger, more irregularly-shaped and smaller,  
regularly-shaped avascular tissue 
Spheroid characterization 
Spheroid morphology was characterized prior to NP administration. Briefly, spheroids were 
removed from culture plates and placed on imaging dishes (P35G-0-14-C, MatTek) in 25 μL of 
culture medium to prevent drying. Spheroids were then imaged using an epifluorescent 
microscope (Axiovision 4, Zeiss) under transmitted light using a 10 × objective (Fig. 2). 
NP distribution 
To assess NP distribution in tumor spheroids, four different NP formulations were evaluated: 
unmodified, PEG, MPG, and MPG/PEG co-treatment groups. Once spheroid formation was 
achieved using the hanging drop (5 days) and liquid overlay (7 days) techniques, fresh culture 
medium was added and spheroids were incubated with 10 μg/mL NPs for 1.5 h. For the NP co-
treatment group, a half-dose of the MPG (5 μg/mL) and PEG (5 μg/mL) NPs were combined for 
a total NP dose of 10 μg/mL. After NP administration, both LO and HD individual tumor 
spheroids, were transferred to eppendorf tubes for fluorescent staining. Due to the differing 
spheroid sizes that result from the LO and HD methods, the total volume transferred was either 
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100 or 50 μL, for LO and HD spheroids, respectively. Once transferred, tumor spheroids were 
washed with 0.2 mL of 1X PBS and fixed with 0.2 mL of 4% paraformaldehyde for 10 min at 
RT. Subsequent to fixation, spheroids were treated with 0.2 mL of 1% Triton-X for 10 min at 
RT. Spheroids were subsequently washed twice with 0.2 mL of PBS, followed by treatment with 
0.2 mL of 4 μg/mL Hoescht in 1% BSA PBS++ (containing CaCl2 and MgCl2) for 10 min at RT 
for nuclear staining. Finally, spheroids were washed in 0.2 mL of PBS and once in 0.2 mL of DI 
water. Spheroids were then transferred to imaging dishes (P35G-0-14-C, MatTek) suspended in 
50 μL PBS. 
NP uptake and distribution through tumor spheroids were assessed via confocal microscopy 
(LSM 710, Zeiss) and image analysis was performed using ImageJ software. The following laser 
settings: 4′ 6-diamidino (DAPI) and GFP were used to visualize Hoechst (blue, cell nuclei) and 
C6 (green, within NPs), respectively. A laser intensity of 2 and a gain of 600 were used for the 
DAPI/Hoechst channel, while a laser intensity of 5 and a gain of 500 were maintained for the 
GFP/C6 channel across experiments. Imaris x64 (v7.7.2, Bitplane) was utilized to generate 3D 
images from the composite z-stacks of the tumor spheroids. These 3D images were then rotated 
90°, forming cross-sections of the tumor spheroids (figure not shown). Using ImageJ, at least 3 
representative samples were taken from the tumor cross-sections to evaluate NP distribution 
within the spheroids. NP penetration was quantified by plotting the mean fluorescence intensity 
(MFI) of each 3D optical reconstruction as a function of distance from the periphery of the 
spheroid towards the midplane. At least 8 fields of view were analyzed per sample, of which the 
averages and standard deviations are reported. NP internalization was then assessed by analyzing 
the area under the curve (AUC, MFI-μm) of the generated distribution profiles using a 
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trapezoidal approximation in Excel. Statistical significance of NP treatment group penetration 
was determined using a one-way ANOVA post hoc Tukey test < 0.05. 
C. RESULTS 
To assess the distribution of unmodified, PEG, MPG, or MPG/PEG co-treatment NPs into hypo-
vascularized cervical cancer tissue regions distal from the point of vascular extravasation, NP 
diffusion was measured in SiHa, CaSki, or HeLa LO or HD spheroids. The area under the curve 
(AUC, MFI-μm) was determined, corresponding to the fluorescence intensity of NPs distributed 
throughout the tumor spheroid, in addition to the maximum mean fluorescence intensity (MFI) 
observed at a given penetration distance for each spheroid and cell type. The maximum MFI 
defines the spheroid depth at which the highest MFI was observed within the tumor spheroid 
after 1.5 h administration. NP penetration and distribution through the spheroids varied as a 
function of surface modification, tissue morphology (LO or HD), and cell type (Figs. 3, 4, 7). 
 
NP characterization 
NP size and morphology were confirmed using SEM imaging and ImageJ processing. 
Unhydrated NPs demonstrated a spherical morphology, with diameters measuring 160 to180 nm 
2. Hydrated NP surface charges were measured using a Zetasizer (Malvern). Unmodified NPs 
had a negative surface charge of − 26.63 ± 1.05 mV; while PEG- and MPG-modified NPs 
measured − 22.03 ± 1.40 and − 8.54 ± 0.35 mV, respectively (Table 1), validating surface ligand 
conjugation. 
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Table 1. Zeta potentials of unmodified, PEG-, and MPG-modified NPs. 
 
 
Spheroid characterization 
In general, the HD spheroids were smaller in size for HeLa, CaSki, and SiHa cells (with 
respective average maximum cross-sectional areas of 0.31, 0.10, and 0.25 mm2) compared to the 
LO spheroids (with respective areas of 0.55, 0.39, and 0.57 mm2)—see Table 1. In addition, for 
both HD and LO spheroids, CaSki tumors demonstrated statistically significant decreases in size, 
relative to HeLa or SiHa spheroids. 
 
Figure 2. Typical morphologies of liquid overlay (LO) and hanging drop (HD) tumor spheroids, 
evaluated via bright feld microscopy. Scale bar: 200 μm 
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Table 2.  Maximum cross-sectional areas of hanging drop (HD) and liquid overlay (LO) tumor 
spheroids as a function of cell type.  All values represent the average ± standard deviation (n=3). 
Tumor Spheroid Surface Area (mm^2) 
  Hanging Drop Liquid Overlay 
HeLa 0.31 ± 0.02 0.55 ± .03 
CaSki 0.10 ± 0.02 0.39 ± 0.04 
SiHa 0.25 ± 0.03 0.57 ± 0.04 
 
NP distribution as a function of cell type and NP formulation was quantified for LO (Fig. 5) and 
HD (Fig. 6) spheroids, respectively. The AUC as a function of NP treatment group and cell type 
are plotted in Fig. 7. Table 3 provides the actual AUC values for each treatment and cell type. 
Despite the minimal distribution observed with unmodified NPs, a statistically significant 
difference was observed between regularly-shaped (HD) and irregularly-shaped (LO) HeLa 
spheroids (AUCs LO 6827 ± 3101 and HD 15,841 ± 1637 MFI-μm), while no statistical 
differences were observed between regularly- and irregularly-shaped CaSki or SiHa cell 
spheroids. Furthermore, unmodified NPs exhibited similar distribution trends within HeLa, 
CaSki, and SiHa spheroids of each type (Figs. 3-6). Within all spheroids, the distribution profiles 
showed that the maximum MFI occurred within 100 μm of the tumor periphery. Moreover, only 
SiHa HD spheroids exhibit a maximum MFI peak above 100 MFI (Fig. 4 and Table 4), 
indicating substantial accumulation of NPs at a given penetration distance. Overall, unmodified 
NPs show no differential penetration and distribution between tumor/cell types and exhibited 
only modest distribution within spheroids, relative to surface-modified NP groups. 
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MPG NP penetration and distribution 
In contrast to the similar distribution profiles of unmodified NPs within a given spheroid or cell 
type, significant differences in distribution were observed for MPG NPs as a function of tissue 
morphology and cell type. In HeLa spheroids, MPG NP distribution (AUC) was found to be 
statistically significant and three times higher in regularly-shaped (HD) spheroids (47,018 ± 
8751 MFI-μm), compared to irregularly-shaped (LO) spheroids (14,339 ± 5129 MFI-μm). 
Similarly, MPG NP distribution was doubled in SiHa regularly-shaped spheroids relative to SiHa 
irregularly-shaped spheroids (AUCs 24,972 ± 2020 and 10,186 ± 2887 MFI-μm). However, a 
minimal difference in MPG NP distribution was observed between CaSki spheroids (Figs. 3-6 
Table 3). Overall, MPG NPs distributed significantly more in HeLa spheroids (47,018 and 
14,339 MFI-μm), relative to the other cell types. 
Additionally, MPG NPs provided much greater intratumoral accumulation when compared to 
unmodified NPs, and the distribution trends varied as a function of cell type. In regularly-shaped 
HD spheroids, MPG NPs penetrated deeper, and accumulated in greater amounts (represented by 
increased MFI) relative to irregularly-shaped LO spheroids. In HeLa regularly-shaped spheroids, 
NPs exhibited the greatest peak in accumulation 129 μm (225 MFI) from the tumor periphery, 
with the second highest peak observed in SiHa cells (222 MFI) 91 μm from the periphery (Fig. 4 
and Table 4). Similar to irregularly-shaped spheroids, NP distribution through regularly-shaped 
CaSki spheroids was dampened by comparison. 
In irregularly-shaped LO HeLa spheroids, MPG NPs demonstrated peaks 76 μm (123 MFI) and 
133 μm (63 MFI) from the periphery (Fig. 3, Table 4). These values were significantly higher 
than exhibited by MPG NPs in irregularly-shaped LO SiHa (MFI 66) or CaSki (MFI 89) tumors. 
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In contrast to these trends, CaSki cells demonstrated gentler and more uniform distribution 
curves, with less pronounced maximum MFIs, similar to unmodified NPs. 
Overall, MPG NPs exhibited increased distribution in the smaller regularly-shaped spheroids 
relative to larger, irregularly-shaped spheroids, across all cell lines. HeLa and SiHa regularly-
shaped spheroids seemed to offer the most permissive environments to MPG NP intratumoral 
distribution and accumulation. 
PEG NP penetration and distribution 
We observed that NPs modified with PEG exhibited variations in tumor penetration and 
distribution as a function of both cell and tissue type. In the larger, irregularly-shaped spheroids, 
PEG NPs had the greatest intratumoral distribution in SiHa cells (AUC 18,972 ± 1065 MFI-μm) 
and exhibited a bimodal distribution trend, relative to the dampened distribution observed in 
irregularly-shaped HeLa and CaSki spheroids (AUCs 4042 ± 2101 and 6718 ± 1065 MFI-μm) 
(Figs. 3-6, Table 3). In contrast, significantly enhanced distribution of PEG NPs was observed 
within the regularly-shaped HD spheroids, with statistically significant increases in PEG NP 
distribution observed in HeLa and SiHa, relative to CaSki spheroids (AUCs 23,140 ± 5531; 
24,237 ± 2532; 14,297 ± 281, respectively). Most notably, PEG NP distribution in regularly-
shaped HeLa spheroids was nearly six-fold greater than in the irregularly-shaped tissue (Figs. 3-
6, Table 3). 
In regularly-shaped HD spheroids, PEG NPs exhibited similar unimodal distribution trends 
across all cell lines. SiHa regularly-shaped spheroids showed the greatest NP accumulation (238 
MFI) occurring 78 μm from the spheroid periphery (Fig. 4, Table 4). Moreover, NPs penetrated 
more deeply, and with higher accumulation, into regularly-shaped HeLa and SiHa spheroids (82 
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and 78 μm), relative to regularly-shaped CaSki spheroids (64 μm). In contrast, PEG NP 
distribution through the irregularly-shaped spheroids varied significantly as a function of cell 
type (Fig. 3, Table 4). In irregularly-shaped LO CaSki spheroids, the observed distribution 
profile was quite dampened, exhibiting a peak of maximum accumulation (62 MFI) only 39 μm 
from the tumor periphery, followed by a decrease in penetration. In comparison, irregularly-
shaped SiHa spheroids exhibited a bimodal distribution of PEG NPs, with minor and major 
maximum peaks (114 and 151 MFI) occurring 62 and 107 μm from the spheroid periphery. In 
contrast, a maximum accumulation of only 42 MFI was reached 203 μm from the spheroid 
periphery for HeLa cells (Fig. 3, Table 4). Overall, PEG NPs exhibited significant penetration 
and distribution in SiHa regularly- as well as irregularly-shaped spheroids, with a maximum 
intratumoral distribution observed in the regularly-shaped HeLa case. 
 
MPG/PEG co-treatment penetration and distribution 
The MPG/PEG NP co-treatment strategy also demonstrated differences in NP distribution as a 
function of tumor and cell type, similar to other modified NP groups. In regularly-shaped 
spheroids, the co-treatment groups demonstrated the greatest distribution in SiHa cells (AUC 
26,970 ± 5574 MFI-μm) (Figs. 4, 6, and Table 3). Similarly, the MPG/PEG co-treatment NPs 
distributed well in HeLa regularly-shaped spheroids (AUC 15,657 ± 3579 MFI-μm), although 
there was no statistical significance observed in the AUC relative to regularly-shaped CaSki cells 
(Figs. 4, 6, and Table 3). In both CaSki spheroid types, the NP co-treatment group exhibited 
statistically decreased levels of distribution relative to that observed in HeLa and SiHa cells. In 
addition, for irregularly-shaped spheroids, insignificant differences in NP distribution were 
observed between HeLa and SiHa cells (AUCs 17,536 ± 2675 and 19,783 ± 1685 MFI-μm), 
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although the distribution trend differed between cell lines (Figs. 3, 5, Table 3). Overall, the 
MPG/PEG co-treatment had the strongest distribution trends (> 15,000 MFI-μm) in the HeLa 
and SiHa spheroids, regardless of tumor type. 
In terms of accumulation and penetration, within the regularly-shaped spheroids (Fig. 4, Table 
4), the MPG/PEG NP co-treatment group exhibited the highest accumulation in SiHa cells 
(maximum peak 239 MFI), relative to that observed in HeLa (154 MFI) and CaSki cells (84 
MFI). However, MPG/PEG NPs exhibited increased penetration in HeLa and CaSki regularly-
shaped spheroids (102 μm and 90 μm, respectively). Additionally, SiHa and HeLa spheroids 
exhibited sharp unimodal peaks, whereas a more diminished distribution was observed in CaSki 
spheroids (Fig. 4). In HeLa and CaSki irregularly-shaped spheroids (Fig. 3), the trends were 
similar as observed in regularly-shaped spheroids, although NPs accumulated and penetrated less 
deeply in irregularly-shaped spheroids and exhibited more modest distribution. Overall, the 
MPG/PEG co-treatment NPs demonstrated the greatest distribution and penetration in SiHa and 
HeLa spheroids representing regularly- and irregularly-shaped avascular tissue. 
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Figure 3. NP distribution through liquid overlay (LO) spheroids in mid-plane cross-sections (top 
three rows) and 3D composite (bottom three rows) confocal images. Nuclei are blue (Hoechst) 
and NPs are green (Coumarin 6). Scale bar: 50 μm 
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Figure 4. NP distribution through hanging drop (HD) spheroids in mid-plane cross-sections (top 
three rows) and 3D composite (bottom three rows) confocal images. Nuclei are blue (Hoechst) 
and NPs are green (Coumarin 6). Scale bar: 50 μm 
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Figure 5. NP distribution profles quantifying the mean fuorescence intensity (MFI) vs. 
penetration distance through liquid overlay (LO) spheroids. Distribution profles are shown as a 
function of NP treatment and tumor cell type. Average of the values along distance is denoted by 
the dark lines. 
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Figure 6. NP distribution profles quantifying the mean fuorescence intensity (MFI) vs. 
penetration distance through hanging drop (HD) spheroids. Distribution profles are shown as a 
function of NP treatment and tumor cell type. Average of the values along distance is denoted by 
the dark lines.  
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D. DISCUSSION 
We have previously evaluated the effect of MPG, PEG, tumor-targeting (VIM), and hybrid 
(MPG + PEG) surface-modified PLGA NPs on NP internalization and distribution in HeLa cell 
monolayers and 3D LO spheroids 2. We found that MPG-modified NPs offered the greatest 
internalization in monolayers and spheroids, and exhibited the highest intratumoral 
accumulation. Yet, despite high levels of distribution and internalization, the most effective 
particle group, MPG NPs, was sequestered within the tumor periphery, while PEG-modified NPs 
penetrated more deeply into the tumor interstitium. Additionally we noted that surface 
modification with opposing ligands on the same NP hindered penetration, which we attributed to 
potential steric hindrance or competing functionalities interacting with the ECM or tumor matrix. 
To expand upon this work, here we evaluate the impact of tumor size, tissue morphology, and 
cell origin on NP distribution. To assess these conditions, we used two different spheroid 
formation methods (LO and HD) to produce 3D spheroids that have been previously shown 170 to 
respectively represent irregularly- or more regularly-shaped hypo-vascularized tumor regions 
distal from the location of vascular extravasation. We evaluated three different cervical 
carcinoma cell lines including HeLa, SiHa, and CaSki cells in both tumor models. Using the 
information gained from these studies, our goal was to provide insight into NP treatment 
strategies that may be applied to different types of tumors. 
We observed that NPs achieved greater distribution in the smaller regularly-shaped spheroids, 
accompanied by increased penetration in HeLa and SiHa HD spheroids, relative to the larger, 
irregularly-shaped LO spheroids. Yet regardless of spheroid formation method, surface-modified 
NPs consistently exhibited increased penetration and distribution, relative to unmodified NPs. In 
irregularly-shaped spheroids, PEG and MPG/PEG co-treatment groups demonstrated the greatest 
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distribution in SiHa cells (AUCs 18,972 ± 1065 and 19,783 ± 1685 MFI-μm), followed by MPG 
and MPG/PEG in HeLa (AUC 14,339 ± 5129 and 17,536 ± 2675 MFI-μm), whereas all NPs 
demonstrated rather modest penetration in irregularly-shaped CaSki spheroids. In comparison, in 
regularly-shaped spheroids, MPG exhibited the greatest distribution (47,018 ± 8754) in HeLa 
cells, with similar modest distribution of all NP groups through CaSki spheroids. In regularly-
shaped SiHa spheroids, MPG, PEG, and MPG/PEG groups exhibited similar distribution (24,972 
± 2020, 24,237 ± 2532, and 26,970 ± 5574 MFI-μm). In both regularly- and irregularly-shaped 
SiHa and HeLa spheroids, we observed only modest distribution of unmodified NPs, relative to 
other NP groups. In CaSki regularly-shaped spheroids, unmodified NPs demonstrated similar 
distribution (12,043 ± 5846 MFI-μm) relative to other NP groups. 
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Figure 7. NP distribution represented as AUC for each tumor cell type (HeLa, SiHa, or CaSki) 
as a function of NP treatment group, relative to spheroid type (LO, black and HD, gray). Values 
of all signifcant correlations, including each treatment group relative to unmodi- fed NPs, 
relative to other treatment groups, or relative to the same treatment group in a diferent spheroid 
type are given with degree of signifcance indicated (* p < 0.01, ** p < 0.001, *** p < 0.0001, 
**** p < 0.00001). Error bars: average ± standard deviation (n = 3) 
 
With these studies in mind, MPG NPs seem to be the most effective treatment group for the 
regularly-shaped HeLa tissue, whereas MPG, PEG, or MPG/PEG co-treatment may be used 
interchangeably for the regularly-shaped SiHa tissue. For larger, irregularly-shaped tissue, MPG 
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and MPG/PEG or PEG and MPG/PEG NPs demonstrated promise for HeLa and SiHas 
respectively. Importantly, the MPG/PEG co-treatment consistently demonstrated NP penetration 
and distribution across all cell types relative to other NP groups, offering a potentially 
comparable treatment option relative to individual groups of surface-modified NPs. In future 
work, the NP co-treatment strategy may offer a significant increase in NP penetration and 
distribution across all cell and tumor types, if administered at the same individual NP 
concentrations as single NP treatments. 
While the tumor microenvironment presents many challenges to achieving efficacious cargo 
delivery, our goal in these studies was to employ rational design to develop more therapeutically 
efficacious drug and gene delivery vehicles to overcome these challenges. One method used to 
enhance the delivery of active agents to cells is to directly complex or conjugate ligands to 
enhance tumor internalization and distribution. Notably, CPPs, such as Tat (the HIV 
transactivator protein) and MPG, have been widely used as drug and oligonucleotide conjugates 
to significantly enhance cellular internalization and localization28,115,158,171-173. In parallel work, 
many groups have conjugated ligands to delivery vehicles, such as NPs, to enhance the 
distribution of larger cargo within and to the tumor microenvironment2,28,159,174-179. 
Another common strategy to enhance NP distribution, has been to modify the NP surface with 
different densities of, and molecular weight PEG molecules. In addition to reducing unwanted 
immune response and increasing the systemic half-life of NPs, this “PEGylation” 13,30,35,79 has 
enabled enhanced NP distribution in normal tissue or mucosal environments such as the female 
reproductive tract, gastrointestinal tract, and lung airways 8,13,28-30,35,39,79,136. Yet despite these 
contributions, there are few studies that have assessed how differences in tumor tissue 
morphology and cell origin, in addition to stealth or cell penetrating NP functionalization affect 
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distribution. Our goal was to assess the impact these factors have on NP distribution through 
hypoxic/avascular regions of the heterogeneously vascularized tumor microenvironment in a 
cervical carcinoma model. In addition to being distal to vasculature and hence liable to receive 
less NPs/drugs, these regions are also usually resistant to cell-cycling drugs due to hypoxia-
induced cell quiescence. The strategy proposed here is to enable more homogeneous and 
increased NP distribution into these regions, and for the NPs to remain long enough to affect 
cells once they resume cycling upon restored access to oxygen/nutrients. 
It is well known that spheroid growth impacts cell proliferation, apoptosis, and necrotic/hypoxic 
core formation (e.g., 180), with the outer layer (width ~100um) mostly proliferative, the middle 
layer hypoxic, and the inner core necrotic, as we have previously observed 181,182. These 
conditions hold true independent of spheroid type 181, as the diffusion of oxygen and nutrients 
into this system maintains cell populations with varying proliferative capability, contributing to 
chemoresistance for cell cycle-specific drugs, and replicates the diffusion limitations of blood-
borne substances observed for tissue in vivo 50,59,152,183. Accordingly, the bulk of NP uptake is 
expected to occur in the spheroid outer proliferative regions, as we have previously measured . 
Applying this knowledge to our studies, we suggest that highly proliferating regions at the tumor 
periphery, representing tissue adjacent to vasculature, combined with dormant/quiescent cells 
within the core, representing tissue distal from nanoparticle point of vascular extravasation, may 
form a gradient in the larger, irregularly-shaped (LO in our studies) tumor microenvironment, 
which may impede NP distribution 184. Therefore we propose that the smaller HD spheroids, 
more closely mimicking regularly-shaped tumor tissue, likely have less structural variability and 
less necrotic tissue, perhaps contributing to the more uniform and increased distribution profiles 
observed.  
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In addition to tumor size and morphology, we observed that NP distribution varied as a function 
of cell type. Indeed, likely as important as tumor size, cell origin plays a significant role in the 
development and diversity of the tumor microenvironment. Overall, we observed that both 
regularly and irregularly-shaped CaSki spheroid types seem to enable significantly less NP 
transport across all treatment groups when compared to SiHa and HeLa spheroids. We postulate 
that this difference in distribution may be due to ability of CaSki cells to form tighter 
intercellular junctions 185, resulting in more regularly-shaped tissue with an intricate interstitial 
microenvironment. In such an environment, we may expect NP distribution to be hindered 
relative to less connected tissue. Further experimental investigation of junctional complex 
expression or integrity will be pursued in follow-up work, and is expected to provide more 
detailed information for optimizing targeting strategies.  Furthermore, it is interesting to note that 
the MPG/PEG co-treatment NPs had consistently high NP distribution across all cell and 
spheroid types, particularly relative to other NP treatment groups in a given cell type. This 
suggests that the dual delivery strategy of MPG/PEG modified NPs is an efficacious treatment to 
penetrate and distribute throughout cervical tumors of different cell origins and varying degrees 
of tissue morphology.  
One factor that may lead to similarities and differences seen between these different cell types is 
that they each possess HPV genomes of different subtypes. Other groups have studied 
immortalized cell lines derived from different tumor subtypes within the female reproductive 
tract to better understand phenotypic expression 186-188. Additionally, the impact of incorporated 
HPV genomes on protein expression within 3D environments has been evaluated. It was 
discovered that HeLa cells, derived from an adenocarcinoma tumor subtype of the cervix, 
contain approximately 20-50 copies of integrated HPV-18, whereas SiHa cells, derived from 
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grade II squamous cell carcinoma, and CaSki cells, derived from cervical epidermoid 
carcinomas, contain approximately 1-2 and 500 copies of integrated HPV-16, respectively 186. 
Previous studies investigating the relationship between gap junctions, connexins, and tumor 
invasion as a function of HPV-related cervical cancer progression found that all three HPV-
associated cervical cancer cell lines were poorly coupled and formed no appreciable gap 
junctions. Furthermore, both SiHa and HeLa cells were observed to have negligible levels of 
Connexin43 (an important transmembrane protein responsible for gap junction assembly), while 
very low levels were expressed in CaSki cells 187. These findings support our observations that 
SiHa and HeLa cells are more permissive to transport than CaSki spheroids possibly due to these 
varying levels of gap junction proteins. Additionally, CaSki cells consistently formed more 
regularly-shaped spheroids, independent of spheroid formation method (HD or LO), indicating 
the impact of cell phenotype on tumor morphology. 
In a separate study, the tumorigenicity of these cell lines was evaluated by observing the tumor 
forming ability post-injection in athymic mice; SiHa and HeLa cells were found to form tumors 
at lower cell density injections relative to CaSki cells. In the same study, SiHa and HeLa cells 
were shown to upregulate cancer-inducing cell-specific genes such as stem-cell markers, 
integrins, and epithelial to mesenchymal transition associated genes, and were found to be highly 
tumorigenic 188. Taking these studies into consideration, it is likely that tumor spheroids formed 
from different cervical carcinoma cell lines generate varying tumor microenvironments and 
therefore affect NP penetration and distribution. Furthermore, it seems that capitalizing on the 
properties of a cationic CPP and neutral, hydrophilic ligand modified NPs may result in 
increased NP distribution through and accumulation in the tumor microenvironment, as shown 
here (Figs. 3-6; Tables 3, 4). 
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IV. Efficacy of Surface-Modified PLGA Nanoparticles to Target  
Hypo-Vascularized Cervical Cancer Lesions. 
 
 
 
 
 
A. CLINICAL SIGNIFICANCE AND BACKGROUND 
 
Cervical cancer is the second leading cause of cancer in women worldwide, contributing to more 
than 275,000 fatalities each year. Additionally, 528,000 new cases were estimated globally in 
2012, accounting for almost 12% of female cancers189. Approximately 85% of cases occur in 
developing countries, with this burden attributed to inadequate screening combined with a lack 
of healthcare190,191. Early detection of pre-cancerous lesions or early stage cervical cancer during 
routine gynecological visits can lead to successful treatment, while undiagnosed disease can 
progress to harder-to-treat advanced stages.  
Early-stage cervical cancer is associated with minimal symptoms and is typically discovered 
during physical or annual exams. Given the limited access that many women still have to 
screening and associated health care, in combination with the minimal symptoms associated with 
stage I disease, approximately 35% of cervical cancers are detected during stages II-III, with 
10% detected during stage IV192,193. For cervical cancer cases that are undiagnosed during the 
early stages, late-stage treatment is limited to highly invasive procedures that include 
radiotherapy, chemotherapy, surgical intervention, or combined therapy. While radiotherapy 
and/or surgery is often used to treat early stage cervical cancer, chemotherapy is common for 
advanced stage cancers194,195. 
A primary challenge facing chemotherapeutic delivery is poor distribution and corresponding 
efficacy, dependent on administration method196,197. Additional challenges include the lack of 
specificity attained with systemic administration, resulting in higher administrated doses to 
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achieve efficacy, increased adverse effects, rapid active agent clearance, and the emergence of 
chemotherapeutic resistance. Localized delivery can circumvent some of these challenges; 
however, both systemic and localized delivery may fail to achieve distribution through the tumor 
tissue. Further, localized delivery to the female reproductive tract (FRT) can facilitate rapid 
vaginal clearance, resulting in difficulty maintaining efficacious concentrations of therapeutic 
agents.  
To address these challenges, nanotherapeutic delivery vehicles have been designed to more 
safely and effectively promote active agent delivery directly to the tumor site and to enhance 
agent distribution within the tumor microenvironment, subsequent to penetration and 
uptake198,199. Nanotherapeutic platforms, such as polymeric nanoparticles (NPs), provide a 
system in which encapsulation of chemotherapeutic agents can be achieved to prolong active 
agent stability and release, while reducing exposure to healthy, surrounding tissue. Furthermore, 
NP accumulation in tumor tissue can be promoted via the enhanced permeability and retention 
(EPR) effect. In particular, FDA-approved polymer-based platforms such as poly(lactic-co-
glycolic) acid (PLGA) NPs, have been engineered to reduce unwanted immunogenic responses, 
avoid organ clearance and tissue transport, target tumor tissue, penetrate the tumor insterstitium, 
improve uptake, and enhance therapeutic efficacy200,201. In addition, these platforms can also be 
tailored by altering the hydrophilic properties of the monomer subunits to reduce the burst 
release of chemotherapeutics or other encapsulated agents, and to provide sustained-delivery, 
corresponding with high uptake and antitumor effects in a variety of in vitro and in vivo cervical 
tumors202.   
The utilization of NP platforms to deliver chemotherapeutic agents has grown more prevalent in 
efforts to overcome the multi-drug resistant (MDR) properties of cervical cancers. Several 
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studies have demonstrated enhanced efficacy of doxorubicin (Dox) by utilizing either inorganic 
or organic NP delivery systems198,203. A recent study investigated the use of folic acid conjugated 
quantum dots to deliver Dox to folate receptor-positive cervical cancer cells, demonstrating 
significant improvement in cellular uptake and therapeutic efficacy204. In a separate study 
utilizing boron nitride NPs loaded with Dox, it was found that these NPs only offered a modest 
therapeutic effect in KB cervical cancer cells relative to leukemia cell lines205. To understand the 
effect of Dox on cervical cancer cells with MDR, the intracellular distribution of Dox was 
investigated and it was found that the use of Dox conjugated NPs significantly changes these 
dynamics, resulting in a high level of Dox within cells, relative to free Dox. Furthermore, PLGA 
NPs incorporating Dox were modified with folic acid-polyethylene-glycol and studied in 
BALB/c mice that had been inoculated with KB cells. Administration of modified PLGA NPs 
significantly increased the efficacy of Dox, resulting in reduced tumor volume in vivo, relative to 
unmodified NPs and free Dox206. These promising results suggest that the use of NP delivery 
platforms may increase the therapeutic efficacy of Dox and other drug candidates, particularly 
for MDR cervical cancers.   
Yet, one of the primary issues hindering the delivery and therapeutic efficacy of 
chemotherapeutics and other active agents is the inability of NPs to penetrate the tumor 
interstitium and, for some applications, undergo internalization by target cells. To overcome 
these transport-based challenges, NPs have been surface-modified with a variety of ligands to 
enhance tumor targeting and distribution. However, cellular internalization and tissue penetration 
are often diametrically opposed. In some cases, surface-modification with targeting or cell 
penetrating ligands, that contain cationic sequences, prevents the carrier from penetrating the 
tumor interstitium due to electrostatic interactions with the extracellular tumor matrix. In 
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contrast, modification with ligands that facilitate penetration may provide broad distribution, but 
decrease internalization at the target cell surface28,207,208 Current NP designs often utilize one of 
these two approaches or iteratively determined ligand combinations to optimize delivery. 
Unfortunately, either case may result in similar ineffective therapy. 
Previously, we investigated the effects of NP surface-modification with cell-penetrating peptides 
(CPPs), stealth ligands, and tumor targeting ligands (MPG (unabbreviated notation), PEG 
(polyethylene glycol), and Vimentin, respectively), on NP penetration and distribution within the 
hypo-vascularized tumor environment2. Nanoparticles modified with the CPP MPG exhibited the 
highest cellular internalization in multi-cellular, human cervical carcinoma (HeLa) 3D spheroids; 
however, internalization primarily occurred within the spheroid periphery, resulting in a modest 
(< 100 μm) tumor penetration depth. In contrast, PEG-modified NPs distributed more deeply into 
spheroids, but were less readily internalized by cells. More recently, we evaluated the penetration 
and distribution of PEG, MPG, and CPP-stealth (MPG/PEG) NP co-treatment strategies as a 
function of tumor morphology and size in 3D spheroid models of hypo-vascularized cervical 
cancer tissue1. The differences in NP distribution as a function of surface-modification 
(unmodified, MPG, PEG, or MPG/PEG co-treatment), spheroid morphology, and cervical cancer 
type, were assessed in HeLa, cervical epithelial adenocarcinoma cells; CaSki, cervical 
epidermoid carcinoma cells; and SiHa, grade II cervical squamous cell carcinoma cells. From 
these studies, it was found that NP tumor distribution varied as a function of tumor size, cervical 
cancer type, and NP surface-modification. Interestingly, relative to unmodified NPs, MPG NPs 
exhibited enhanced distribution in HeLa spheroids, whereas PEG NPs were observed to have the 
greatest distribution in SiHa spheroids, for both small, homogeneously shaped and large, 
irregularly shaped tumors. Furthermore, it was noted that co-treatment of tumors with MPG- and 
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PEG-modified NPs resulted in comparable distribution and tumor penetration across all tissue 
and tumor types, suggesting the potential for rational design to elicit the most efficacious 
treatment in vivo, in which the tumor architecture and composition are profoundly more complex 
than 3D spheroid cell cultures.  
Building upon this previous work, the goal of this study was to determine the therapeutic 
efficacy imparted by these different delivery vehicles across different cervical tumor types. The 
chemotherapeutic agent, Dox, was incorporated into PLGA NPs with PEG, MPG, or PEG/MPG 
modifications to assess the differences in efficacy imparted as a function of surface modification, 
transport, and cell type.  The NP efficacy in 2D cervical cancer monolayers and 3D tumor 
spheroids were assessed to characterize the different effects of treatment and to overcome the 
limitations of 2D testing.  The chemotherapeutic Dox was used due to its application in a variety 
of chemotherapeutic regimens, including cervical cancer, and its ability to affect tumor cells at 
any stage of the cell cycle 209,210. Moreover, while Dox has proven efficacious in killing both 
blood cancers and solid tumors, it is limited by the development of drug resistance, primarily 
caused by drug-resistant pumps such as P-glycoprotein (Pgp). Doxorubicin is also associated 
with acute side effects such as inducing cardiomyopathy, due to non-specific targeting.  These 
limitations offer opportunities for engineered delivery systems to improve upon the clinical 
efficacy of Dox. 
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B. METHODS 
Synthesis of Avidin-Palmitate Conjugates 
Avidin-palmitate was synthesized for subsequent conjugation to NPs as previously described 
20,22,23,26. Briefly, 40 mg of avidin (A9275, Sigma) was dissolved in 4.8 mL of 2% sodium 
deoxycholate (NaDC) in phosphate buffered saline (PBS) warmed to 37°C. Palmitic acid-NHS 
(PA-NHS, Sigma) was dissolved in 2% NaDC to a final concentration of 1 mg/mL and sonicated 
until well-mixed. PA-NHS solution (3.2 mL) was added dropwise to the avidin NaDC solution, 
and reacted overnight at 37°C. The following day, the reaction was dialyzed in 1200 mL of 
0.15% NaDC in PBS heated to 37°C. Free PA-NHS was dialyzed overnight at 37°C using 3500 
MWCO tubing to remove free palmitic acid. After overnight dialysis, the dialysis tubing contents 
were transferred to a storage vial and stored at 4°C until use. 
 
Nanoparticle Synthesis 
PLGA NPs encapsulating either the fluorophore Coumarin 6 (C6) or the chemotherapeutic 
doxorubicin (Dox) were synthesized as previously described1,2 to enable visualization via 
fluorescence microscopy and induce cell death, respectively. Briefly, NPs were synthesized 
using an oil-in-water (o/w) single emulsion technique 1,2. Carboxyl-terminated poly(lactic co-
glycolic acid, PLGA) (0.55-0.75 dL/g, LACTEL®) was used to synthesize 100-200 mg batches. 
Encapsulant was dissolved in methylene chloride (DCM) overnight at a concentration of 15 μg 
C6 per mg of PLGA or 100 μg Dox per mg PLGA. The following day, the 
PLGA/encapsulant/DCM solution was added dropwise to a 5% polyvinyl alcohol (PVA) solution 
of equal volume, vortexed, and sonicated. The resulting NPs were hardened in 0.3% PVA during 
solvent evaporation for 3 hr. 
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Unmodified NPs were washed after hardening, and centrifuged at 4°C, 3 times in deionized 
water (diH2O) to remove residual solvent. Nanoparticles were frozen, lyophilized, and stored at -
20°C until use. A similar protocol was followed to synthesize MPG (3177 Da, GenScript) and 
PEG (5000 Da, Nanocs Inc.) surface-modified NPs, with the addition of avidin-palmitate (5 
mg/mL) to the 5% PVA solution. Surface-modified NPs were collected after the first wash, and 
incubated for 30 min. with biotinylated ligands at a molar ratio of 3:1 ligand:avidin in PBS. After 
the conjugation reaction, the NPs were washed two more times with diH2O centrifugation, 
frozen, and lyophilized. All NPs were stored at -20°C after synthesis.  
 
Nanoparticle Characterization 
NP Physical Properties 
NP characterization confirmed the physical properties of NPs including unhydrated diameter, 
morphology, and surface charge. Scanning electron microscopy (SEM, Zeiss SUPRA 35VP) was 
utilized to verify unhydrated NP morphologies and diameters, measured using NIH ImageJ 
software. The NP zeta potentials  were characterized using a Malvern Zetasizer (Zetasizer Nano 
ZS90).  
 
Controlled Release and Encapsulation 
To determine the loading and release properties of Dox NPs, encapsulation and controlled 
release experiments were conducted. To evaluate loading and encapsulation efficiency, 
approximately 3-5 mg of Dox NPs were suspended in 1 mL of DMSO for 30 minutes to dissolve 
the PLGA polymer matrix. Subsequently, the quantity of Dox loaded was determined by 
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measuring the fluorescence (480nm) and comparing to a calibrated Dox standard. The sustained-
release properties of Dox NPs were determined by assessing controlled release in vitro. Dox NPs 
were resuspended in 1 mL of 1X PBS (pH 7.4) at a concentration of 2mg/mL and incubated with 
gentle agitation at 37ᵒC. At fixed time points (1, 2, 4, 6, 24, 48, 72, 96 hr, 1, 2, 3, and 4 wk), 
samples were collected and the amount of Dox released from the NPs was quantified using 
absorbance (480nm) as described above. 
Three-Dimensional Cell Culture 
The human cervical carcinoma cell lines, SiHa, and CaSki (ATCC), were kindly provided by Dr. 
Alfred Jenson (University of Louisville), while the HeLa cell line was generously provided by 
Dr. Kenneth Palmer (University of Louisville). HeLa and SiHa cells were maintained in 
Minimum Essential Media (MEM) and CaSki cells were maintained in RPMI medium, both 
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin.  All cells were kept 
in a humidified atmosphere of 5% CO2 at 37°C, and were grown to 80% confluence prior to 
tumor spheroid formation.  
 
Hanging Drop Tumor Spheroid Formation 
To form hanging drop spheroids, ultra-low attachment plates (#4515, Corning) were utilized. 
Briefly, cells were trypsinized after reaching 80-90% confluency and seeded at a density of 5,000 
cells per well in 100 μL culture medium. Care was taken to minimize pipette tip contact with 
ultra-low attachment plate well walls. Spheroids were allowed to form for 5 days under the cell 
culture conditions described above. 
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Spheroid Characterization 
Spheroid morphology was characterized prior to NP administration. Briefly, spheroids were 
removed from culture plates and placed on imaging dishes (P35G-0-14-C, MatTek) in 25 μL of 
culture medium to prevent drying. Spheroids were then imaged with an epifluorescent 
microscope (Axiovision 4, Zeiss) under transmitted light using a 10X objective.   
 
Flow Cytometry 
The association and internalization of NPs were determined using fluorescence-activated cell 
sorting (FACS). The four NP formulations: unmodified, PEG, MPG, and MPG/PEG co-
treatment groups, were added to hanging drop spheroids for 1.5 or 24 hr. After incubation, the 
spheroids were collected in 2 mL eppendorf tubes and washed three times with PBS to remove 
unbound NPs. Trypsin-EDTA (0.25%) was added to the spheroids for 5 min to dissociate the 
spheroids. Trypsinized cells were subsequently moved to FACS tubes, centrifuged, and 
resuspended in a FACS buffer solution containing 1 % BSA and 0.1 % sodium azide. From each 
sample, half the cells were moved to separate FACS tubes and kept on ice until analyzed (total 
associated samples). The remaining cells were exposed to 0.4 % trypan blue for 5 min to quench 
extracellular fluorescence, washed twice in FACS buffer, and kept on ice until analyzed 
(internalized samples) [31]. All FACS tubes from both groups were analyzed using a BD 
LSRFortessa Flow Cytometer (BD Biosciences). Data were analyzed using FlowJo software 
(FlowJo Enterprise), and a minimum of 2,500 cells were analyzed per sample. 
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NP Efficacy in Cervical Cancer Monolayers and Spheroids 
2D Chemotherapeutic Efficacy 
The chemotherapeutic efficacy of surface-modified Dox NPs in 2D monolayer cell cultures was 
determined via the  MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) cell 
proliferation assay. Cervical carcinoma cells were seeded at a density of 1.5x103 cells per well 
and allowed to adhere overnight. Serial dilutions of surface-modified Dox NPs at a maximum 
NP concentration of 5 mg/mL, were administered to cell monolayers. Untreated cells and cells 
treated with 10% DMSO were used as positive and negative controls of viability, respectively. 
Cells were then incubated under normal cell culture conditions for 24 hr. Following NP 
administration, media was discarded and replaced with 100 μL of fresh PBS. Plates were then 
centrifuged at 300 rpm for 5 min, to remove free NPs. The PBS supernatant was discarded from 
the wells, and 10 μL MTT reagent was added to each well in the absence of light. Plates were 
subsequently incubated under normal cell culture conditions for 4 hr. Following incubation, 50 
μL lysis buffer (10% SDS in 0.01M HCl) was added to each well and placed in the incubator 
overnight. Sample absorbance was quantified (570 nm) the next day.  
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3D Chemotherapeutic Efficacy 
To assess NP cytotoxicity in tumor spheroids, four different NP formulations were evaluated: 
unmodified, PEG, MPG, and MPG/PEG co-treatment groups. Once spheroid formation was 
achieved using the hanging drop method (5 days), fresh culture medium was added and the 
spheroids were transferred to 96-well opaque plates with 100 μL media and NP treatments for 24 
hr. For the NP co-treatment group, a half-dose of the MPG and PEG NPs were combined for a 
total NP dose of the desired concentration. After the 24 hr, the plated spheroids were removed 
from the incubator and equilibrated for 30 min. Cell Titre-Glo (100 μL) was added to each well, 
and the plate contents were mixed vigorously for 5 min on a reciprocating shaker. After mixing, 
the spheroids were incubated at room temperature for 25 min and luminescence was recorded on 
a BioTek Synergy HT luminometer. 
 
Statistical analysis 
Experiments were conducted each with a minimum sample size of n = 6. Data were analyzed by 
using a two-way ANOVA applying Tukey’s test (* p < 0.01, ** p < 0.001, *** p < 0.0001, **** 
p < 0.00001). 
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C. RESULTS 
Nanoparticle Characterization 
Size and Morphology 
NP size and morphology were confirmed using SEM and ImageJ processing. Unhydrated NPs 
demonstrated a spherical morphology, with diameters ranging between 160 to 180 nm 1,2.  
Hydrated NP surface charges were measured using a Zetasizer (Malvern). Unmodified NPs had a 
negative surface charge of -14.8 ± 1.2 mV; while PEG- and MPG-modified NPs measured 0.1 ± 
0.4 and 0.7 ± 0.3 mV, respectively, validating surface ligand conjugation. 
 
 
Loading and Release 
Doxorubicin loading and encapsulation efficiency within MPG, PEG, and unmodified NPs were 
assessed (Table 1). MPG and PEG NPs exhibited significant increases in drug loading (65.9 ± 
2.3 μg/mg and 75.7 ± 6.8 μg/mg) and encapsulation efficiency (66% and 76%), relative to 
unmodified NPs (28.9 ± 1.5 μg/mg and 29% respectively).The in vitro release of Dox was 
characterized during a 24 hr release study (Fig. 1). The unmodified NPs released approximately 
95% of the encapsulated Dox payload during the first 24 hr, while MPG and PEG NPs released 
~80-90% during the same duration.  
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Figure 1. The cumulative release of Dox from unmodified (triangle), MPG (circle), and PEG 
(square) modified NPs, as a function of (A) NP mass and (B) percent total loading. 
 
Table 1. Nanoparticle loading and encapsulation efficiency. 
 
Spheroid Morphology and Nanoparticle Association 
Cervical tumor spheroids were formed from each HeLa, SiHa, and CaSki cell lines. Spheroid 
morphology was found to be dependent upon cervical tumor type (Fig. 2), as previously 
observed1. Overall it was observed that HeLa cells demonstrated the most diffuse morphology, 
while CaSki cells formed the most dense tumor spheroids. 
 
NP Formulation Concentration (g Dox per mg NP) % Encapsulation 
MPG 65.9 ± 2.3 66% 
PEG 75.7 ± 6.8 76% 
Unmodified 28.9 ± 1.5 29% 
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Figure 2. Fluorescent cross-sectional images of cervical tumor spheroids comprised of (A) HeLa, (B) 
SiHa, and (C) CaSki cells stained with Hoechst dye. 
 
To assess differences in NP localization as a function of spheroid morphology, NP association 
and internalization were evaluated in HeLa, SiHa, and CaSki cells, following incubation times of 
1.5 and 24 hr (Fig. 3). Differences in association (bound plus internalized), relative to 
internalization, varied as a function of both incubation time and cell type.  
Within the HeLa spheroids (Fig. 2A), MPG NPs exhibited statistically significant increases in 
cellular association after 24 hr administration, relative to unmodified and PEG NPs. Co-
treatment NPs (MPG/PEG) had the second highest NP association although no statistical 
significance was observed relative to other NP groups. Similarly, MPG NPs demonstrated the 
highest cellular internalization in HeLa spheroids, although no statistically significant differences 
in internalization were observed relative to other NP treatment groups.  
In the similarly sized, but less amorphous SiHa spheroids (Fig. 2B), unmodified NPs had the 
highest association followed by MPG NPs (Fig. 3). Moreover, all surface-modified NP groups 
exhibited trends of increased cellular internalization in SiHa spheroids relative to unmodified 
NPs; however, no statistical differences were observed between NP groups.  
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In the smaller, densely structured CaSki spheroids, NP association and internalization were 
reduced across all treatment groups relative to that observed in HeLa and SiHa spheroids. 
MPG/PEG co-treatment NPs had statistically increased cellular association with respect to all NP 
groups. MPG NPs exhibited the second highest degree of NP association and PEG NPs were 
shown to have the lowest amount of NP association, relative to all other treatment groups. The 
MPG/PEG co-treatment NPs also had statistically higher levels of cell internalization in CaSki 
spheroids after 24 hr, relative to all other treatment groups. 
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Figure 3. NP association (binding plus internalization, black) and internalization (grey) in 3D 
tumor spheroids after 1.5 hr (left) and 24 hr (right) administration. 
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Nanoparticle Efficacy against Cervical Cancer Monolayers and Spheroids 
To relate NP localization to chemotherapeutic efficacy, surface-modified NPs were administered 
to 2D cervical cell monolayers (Fig. 4) and 3D tumor spheroids (Fig. 5). The concentration at 
which 50% of cell growth was inhibited (IC50) was evaluated for each NP treatment group as a 
function of Dox concentration (Figs. 4 and 5, Tables 2) and NP dose (data not shown). The 
efficacy imparted by NPs was found to vary as a function of cervical tumor and NP modification 
type. Figure 6 provides a summary of all IC50s across monolayers and spheroids, as a function 
of Dox and NP concentrations.  
 
NP Efficacy in HeLa Cells 
The efficacy of surface-modified Dox NPs was assessed relative to unmodified NPs and free 
Dox in different cervical cell type monolayers and spheroids, after 24 hr administration. In HeLa 
spheroids, the MPG/PEG co-treatment NP group demonstrated a statistically significant increase 
in efficacy (IC50 13.3 ± 0.64 μM) relative to other NP groups. Free doxorubicin evinced a 
statistically significant increase in efficacy relative to NP treatment groups but statistically 
similar efficacy to the MPG/PEG co-treatment. Of the surface-modified groups, MPG NPs (IC50 
31.9 ± 6.5 μM) performed slightly better, but statistically similar to PEG and unmodified NPs 
(34.7 ± 1.6 μM and 33.4 ± 5.5 μM, respectively), all of which had a statistically significant 
higher IC50 value relative to free Dox and the MPG/PEG NP co-treatment (IC50s 8.7 ± 1.3 and 
13.3 ± 0.64 μM, respectively). Overall, the MPG/PEG NP co-treatment was the most efficacious 
NP group in HeLa spheroids.  
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In HeLa monolayers unmodified NPs demonstrated the greatest efficacy, with a statistically 
significant decrease in IC50 (20.3 ± 2.2 μM) relative to surface-modified NP groups (MPG 28.6, 
PEG 39.5, and MPG/PEG 35.8 μM) and free Dox (25.4 ± 3.9 μM). Similar to HeLa spheroids, 
PEG NPs were the least promising treatment group (39.5 ± 7.5 μM) in HeLa monolayers. 
 
NP Efficacy in SiHa Cells 
Relative to their modest efficacy in HeLa spheroids, unmodified NPs exhibited the greatest 
efficacy relative to other surface-modified NP groups in SiHa spheroids. Unmodified NPs 
exhibited a statistically lower IC50 (14.7 ± 0.6), relative to MPG (30.2 ± 1.2), PEG (23.3 ± 1.1 
μM), and the MPG/PEG co-treatment NPs (28.4 ± 4.2 μM).  Overall, MPG and the MPG/PEG 
co-treatment NPs were observed to be the least efficacious formulations in SiHa spheroids (30.2 
± 1.2 and 28.4 ± 4.2 μM, no statistical differences). All NPs provided modest efficacy against 
SiHa spheroids. Similar to HeLa spheroids, free Dox exhibited the lowest IC50 (11.9 ± 2.9 μM), 
with statistical significance observed relative to all NP groups.  
 
In SiHa monolayers, PEG and co-treatment NP groups exhibited the strongest efficacy (IC50s 
22.6 ± 3.9 μM and 27.2 ± 3.3 μM) with statistically improved efficacy relative to free Dox (IC50 
42.3 ± 13.7 μM). Overall, unmodified, PEG, and co-treatment NPs had similar IC50 values. 
Similar to 3D spheroids, MPG NPs (IC50 34.1 ± 8.5 μM) were the least efficacious NP 
formulation, demonstrating comparable efficacy to free Dox (42.3 ± 13.7 μM). While PEG and 
unmodified NPs showed the greatest efficacy in SiHa spheroids, PEG and co-treatment NPs 
performed most efficaciously in SiHa monolayers. 
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NP Efficacy in CaSki Cells 
Relative to the efficacy trends observed in HeLa and SiHa spheroids, the efficacy of NP groups 
within CaSki spheroids varied. Overall, PEG NPs were the most efficacious treatment group in 
CaSki spheroids (IC50 13.1 ± 1.1 μM), demonstrating a statistically significant improvement in 
efficacy relative to all other treatment groups. MPG NPs exhibited the second highest NP 
efficacy (IC50 22.5 ± 3.2 μM) followed by unmodified NPs (25.38 ± 2.6 μM) and the MPG/PEG 
co-treatment group (25.6 ± 3.7 μM). However, no statistical significance was observed between 
unmodified, MPG, and co-treatment NPs. As in HeLa and SiHa spheroids, free Dox exhibited 
the lowest IC50 (1.8 ± 0.5 μM), relative to all NP groups. Overall, PEG NPs and free Dox were 
most efficacious in CaSki spheroids. 
 
Within CaSki monolayers, all NP groups demonstrated statistically significant improvements in 
efficacy, relative to free Dox. Within the NP groups, MPG/PEG co-treatment NPs were 
significantly more efficacious than MPG NPs (IC50s 18.1 ± 2.3 and 31.3 ± 5.4 μM), and 
demonstrated similar efficacy to PEG and unmodified NPs. Furthermore, the co-treatment NP 
group was the most efficacious treatment, while MPG NPs were the least efficacious group, 
relative to free Dox. Overall, PEG NPs were the most effective treatment group in CaSki 
spheroids, while the MPG/PEG co-treatment NP group was the most promising formulation in 
CaSki monolayers.  
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Figure 4. The cytotoxicity of surface-modified Dox NPs and free Dox in HeLa, SiHa, and CaSki 
cervical carcinoma monolayers after 24 hr administration, as a function of Dox dose. 
 
Figure 5. The cytotoxicity of surface-modified Dox NPs and free Dox in HeLa, SiHa, and CaSki 
cervical carcinoma 3D tumor spheroids after 24 hr administration, as a function of Dox dose. 
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Figure 6. The IC50s of surface-modified NPs after 24 hr administration in cervical carcinoma 
monolayers (top) and 3D tumor spheroids (bottom) as a function of Dox (A and C, μM) and NP 
(B and D, mg/mL) concentrations. 
 
Table 2.  IC50 Values of Surface-Modified Dox NPs and Free Dox in Cervical Cancer 
Monolayers and Tumor Spheroids Expressed in Terms of Dox Concentration. 
Cervical Cancer  
Cell Model 
Doxorubicin IC50 [μM] 
Free Dox Unmodified NPs MPG NPs PEG NPs Co-Treatment NPs 
Monolayers 
HeLa 25.4 ± 3.9 20.3 ± 2.2 28.6 ± 4.0 39.5 ± 7.5 35.8 ± 8.6 
SiHa 42.3 ± 13.7 27.7  ± 5.8 34.1 ± 8.5 22.6 ± 3.9 27.2 ± 3.3 
CaSki 41.4 ± 10.5 29.7 ± 7.9 31.27 ± 5.4 23.4 ± 4.5 18.1 ± 2.3 
Spheroids 
 
HeLa 8.7 ± 1.3  33.4 ± 5.5 31.9 ± 6.5 34.7 ± 1.6 13.3 ± 0.64 
SiHa 11.9 ± 2.9  14.7 ± 0.6 30.2 ± 1.2 23.3 ± 1.1 28.4 ± 4.2 
CaSki 1.8 ± 0.5 25.38 ± 2.6 22.5 ± 3.2 13.1 ± 1.1 25.6 ± 3.7 
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Evaluation of NP Efficacy Based on NP Distribution 
Lastly, we assessed how the NP distribution in the 3D cell cultures of the various cell types, as 
observed in our previous work1, related to their efficacy measured in this study (Table 3). 
.   
Table 3.  Comparison of NP efficacy (measured as IC50 in this study) to NP distribution 
(quantified as area-under-the-curve, AUC (MFI-μm), in 1) and maximum penetration (measured 
as mean fluorescence intensity (MFI) as a function of maximum penetration depth (μm), in 1) in 
3D cell culture of various cervical cancer cell types. 
NP Measurement Cell Type Unmodified MPG PEG Co-Treatment 
Distribution shown as AUC 
(MFI-μm) 
HeLa 15841 ± 1637 47018 ± 8754 23140 ± 5531 15657 ± 3579 
SiHa 14673 ± 543 24972 ± 2020 24237 ± 2532 26970 ± 5574 
CaSki 9331 ± 1090 12364 ± 1485 14297 ± 281 11847 ± 2231 
Fluorescence Observed at 
Max. Penetration Depth 
(MFI, μm) 
HeLa (99, 85) (225, 129) (217, 82) (154, 102) 
SiHa (123, 61) (222, 91) (135, 64) (239, 84) 
CaSki (83, 52) (101, 66) (238, 78) (84, 90) 
Efficacy shown as IC50 
(μM) 
HeLa 33.4 ± 5.5 31.9 ± 6.5 34.7 ± 1.6 13.3 ± 0.64 
SiHa 14.7 ± 0.6 30.2 ± 1.2 23.3 ± 1.1 28.4 ± 4.2 
CaSki 25.4 ± 2.6 22.5 ± 3.2 13.1 ± 1.1 25.6 ± 3.7 
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D. DISCUSSION 
In previous work we investigated the effect of surface modification on NP penetration and cell 
internalization in cervical tumor tissue2. In both HeLa monolayers and spheroids, nanoparticles 
modified with the CPP MPG exhibited the highest cellular internalization. However, 
internalization primarily occurred within the spheroid periphery, resulting in a modest (< 100 
μm) tumor penetration depth. In contrast, PEG-modified NPs distributed most deeply into 
spheroids, but were less readily internalized by cells, underscoring the dichotomous transport 
properties of NPs modified with a CPP, relative to a neutral “stealth” ligand.   
To expand upon this work, we subsequently evaluated surface-modified NP distribution through 
cervical tumors, as a function of cervical tumor type and morphology1. We found that 
distribution varied as a function of cervical cancer type and tissue morphology, in addition to NP 
surface-modification. In small, homogeneously shaped avascular tumors, enhanced distribution 
was observed for MPG and PEG NPs in HeLa, and for all surface-modified NPs in SiHa 
spheroids, relative to unmodified NPs. In larger, more irregularly-shaped spheroids, the greatest 
distribution was observed for MPG and MPG/PEG co-treatment NPs in HeLa, and for PEG and 
MPG/PEG co-treatment NPs in SiHa spheroids1. In contrast, small, densely structured CaSki 
spheroids exhibited modest distribution across all NP groups. Overall, for a given tumor type, 
surface modifications were found to benefit tumor distribution, relative to utilization of 
unmodified NPs. These results suggested that co-treatment strategies may overcome the 
obstacles associated with NP tumor penetration and distribution, and may influence the design of 
delivery platforms for cancer therapy, especially for tumors expected to present both regularly- 
and irregularly-shaped tissue regions.   
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Given these observations, the aim of this study was to relate the transport properties of surface-
modified NPs to therapeutic efficacy as a function of cervical cancer type. To evaluate this, the 
efficacy of unmodified and surface-modified NPs, encapsulating the chemotherapeutic Dox, was 
assessed in three cervical carcinoma cell lines (HeLa, SiHa, and CaSki), grown as 3D spheroids 
to represent tumor lesions with a hypervascularized periphery and hypovascularized interior. We 
selected Dox, as it is a commonly used chemotherapeutic; however, its efficacy against cervical 
tumors has been limited due to the MDR of several cervical cancer types, including HeLa, SiHa, 
and CaSki lines. We hypothesized that the use of NPs may significantly increase the therapeutic 
efficacy of Dox, by increasing intracellular Dox accumulation, as MDR cells are prone to have 
more drug efflux due to an increased presence of p-glycoprotein pumps198,211. Moreover, the 
mechanism of action of Dox intercalation with DNA, inducing topoisomerase II inhibition and 
cellular DNA damage, makes it a model drug to represent active agents that must internalize to 
elicit therapeutic effect.  
While the purpose of this study was to assess the effect of NP surface-functionalization on 
cervical tumor cytotoxicity, drug loading and release have integral roles in achieving therapeutic 
effect. The modest encapsulation efficiencies of unmodified NPs (29%), relative to MPG- and 
PEG-modified NPs (66 and 76% of Dox, respectively, Table 1), resulted in variations of release 
quantity with respect to time. Unmodified NPs released 28.3 ± 2.1 μg Dox/mg NP within 24 hr, 
while MPG and PEG NPs exhibited significantly higher release (66.5 ± 2.6 and 67.2 ± 12 μg 
Dox/mg NP, respectively) during the same duration (Fig. 1).   
When compared as a function of Dox concentration, relative to NP dose, these loading and 
release differences had an impact on therapeutic efficacy (measured as the IC50). For example, 
unmodified NPs, which were the most efficacious in SiHa spheroids (14.7 ± 0.6 μM, Fig. 6, 
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Table 2) as a function of Dox concentration, required a higher NP dose (3-5 mg/mL, data not 
shown), relative to surface-modified NPs, to achieve efficacy across all tumor types (HeLa, 
SiHa, CaSki). Furthermore, although they demonstrated modest efficacy relative to other NP 
treatment groups, unmodified NPs were still more efficacious than free Dox in CaSki and HeLa 
monolayers. Therefore, discrepancies in therapeutic efficacy as a function of NP dose relative to 
Dox dose, may be attributed to the approximately 2-fold lower drug loading and corresponding 
lower release observed with unmodified NPs. Moreover, surface-modified NPs may release less 
encapsulant during the fabrication process, contributing to overall higher loading post-
fabrication. These observations confirm the need to quantify therapeutic efficacy as a function of 
both drug release and NP dosing.  
In addition to cytotoxicity differences based on NP loading and release profiles, the therapeutic 
efficacy of surface-modified NPs varied as function of cell type and NP surface modification. 
While unmodified NPs were most efficacious in SiHa spheroids as a function of Dox 
concentration, MPG/PEG co-treatment and PEG NPs were the most efficacious groups in HeLa 
and CaSki spheroids, respectively. Notably, in the more densely packed CaSki spheroids, PEG 
NPs were the most efficacious; however, all NP groups were less efficacious than free Dox 
alone. These results suggest specific surface modifications, dependent on tumor type, may elicit 
similar therapeutic effect as free Dox. Together, these results are consistent with the fact that 
tumor cell type and the associated microenvironment significantly impact therapeutic efficacy.  
Together with the effects of the tumor microenvironment alone, the effect of active agent on the 
tumor microenvironment has been explored to better understand poor efficacy. Previous work 
investigated the effect of free Dox in tumor spheroids, and found that HeLa spheroids retained 
morphology and proliferated, even after treatment with a range of Dox concentrations (0-40 
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μM)212. One proposed reason was that the extracellular matrix within the spheroid 
microenvironment remains intact following cell death212. Specifically for Dox, it was observed 
that efficacious levels of Dox failed to be internalized within 24 hr, resulting in reduced 
cytotoxic effect. Considering this, the use of specific NP modifications, while providing similar 
or less efficaciousness dependent on tumor type, may provide benefit within the real tumor 
microenvironment, by minimizing drug toxicity to surrounding tissue, providing longer 
exposure, and enhanced distribution. Moreover, NP diffusion, relative to free Dox delivery, may 
promote NP immobilization in the tumor matrix, prolonging the effects of localized cell death 
while reducing overall systemic cytotoxicity.  
In addition to drug-specific effects on the tumor microenvironment, the effect of tumor density 
has been determined to play a role in the pharmacokinetics of chemotherapeutics within solid 
tumors. In particular, tumors that have a reduced tissue density have increased molecule 
penetration196,213-215. Similarly, in our previous studies, we observed that the decreased density of 
HeLa and SiHa spheroids, relative to CaSki spheroids correlated to increased levels of NP 
penetration1. Additionally, the difference in levels of HPV genome incorporation and oncogenic 
E6/E7 expression between cervical tumor cells underscores the variations in spheroid growth and 
permeability as a function of cell type186,216. In studies by Hoppe-Seyler and group, it was found 
that the expression of rate-limiting glycolytic enzymes was significantly influenced by 
incorporation of HPV oncogenes E6/E7, leading to enhanced rates of aerobic glycolysis217. The 
investigation revealed the presence of these enzymes was dramatically elevated in HeLa cells, 
relative to CaSki and SiHa. This propensity for HeLa cells to have enhanced rates of aerobic 
glycolysis could significantly impact the gradient of proliferating cells in the tumor 
microenvironment. Another study by the same group found that under hypoxic conditions, HPV-
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positive cells can undergo a reversible state of dormancy and avoid senescence218. This effect 
could also contribute to variations in regions of proliferating versus dormant cells and impact the 
microenvironment at regions of gradient transition within the tissue.   
As well as the effects observed from oncogenic expression, other work has evaluated the role of 
gap junction formation in immortalized cervical cancer cell progression. These studies revealed 
that both HeLa and SiHa cells have negligible levels of Connexin 43 relative to CaSki cells, and 
therefore exhibit lower levels of gap junction formation187. This is in agreement with our current 
and previous work, in which we observed that CaSki cells consistently form compact, dense 
spheroids that are less permissive to NP transport1. The dependency of pharmacokinetics on 
tumor spheroid intercellular interactions and cell density may also contribute to the increase in 
efficacy of MPG/PEG co-treatment NPs in HeLa spheroids relative to SiHa and CaSki spheroids. 
The more permeable nature of HeLa spheroids may be favorable for both MPG and PEG 
surface-modified NPs to more easily diffuse through the spheroid. Alternatively, as in our 
previous work1,2, the different distribution profiles of MPG and PEG NPs, may benefit from co-
administration strategies (here, MPG/PEG co-treatment) that target tumor cells in different tumor 
regions (MPG: periphery, PEG: core). In contrast, the increased efficacy of unmodified NPs in 
SiHa spheroids and PEG NPs in CaSki spheroids, relative to the co-treatment in the less 
amorphous spheroids, suggests the advantage modification may have in enabling the delivery of 
therapeutically effective levels of active agent in tumors of increasing variability and unique 
microenvironment conditions. 
Another aspect of NP efficacy that is often overlooked, is the relationship between transport and 
NP association and internalization at their target site. Thus, increased NP distribution and 
penetration into tumor tissue may not necessarily correlate with improved efficacy (Table 3). 
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While it has been previously established that Dox must be internalized to exert therapeutic effect, 
NPs add an additional layer of complexity (yet potential enhancement) to the delivery process. 
To relate these properties, total NP association (binding and internalization) and internalization 
were assessed, dependent on cell and surface-modification type.  
In HeLa spheroids, MPG NPs had the highest levels of cell association (bound extracellularly as 
well as internalized, 6823 MFI) relative to all other NP groups after 24 hr administration, with 
statistical significance observed relative to unmodified and PEG NPs (Fig. 3). Although there 
was no statistical difference between NP groups for cell internalization (Fig. 3), the association 
results suggest that MPG NPs may be interacting with the extracellular components of the tumor 
periphery where proliferating cells are present, while PEG NPs encounter fewer interactions with 
the tumor microenvironment and diffuse more freely through the spheroid. This transport 
behavior, observed also in our previous work1, may support the increase in efficacy of the 
MPG/PEG co-treatment NPs observed, particularly in more amorphously-shaped HeLa 
spheroids.  
In SiHa spheroids, there were no statistical differences between NP groups for cell association 
after 24 hr. (Fig. 3). Similarly, while all surface-modified NPs exhibited trends of improved cell 
internalization in SiHa spheroids relative to unmodified NPs, no statistical significance was 
observed (Fig. 3). Here we hypothesize that even slight increases in cell association, seen with 
unmodified NPs, may correlate with the increase in therapeutic efficacy of unmodified NPs, 
relative to surface-modified NPs in SiHa spheroids. These results support the idea that tumor 
distribution must be considered to effectively deliver therapeutic levels of Dox within the TME.  
In CaSki spheroids, the MPG/PEG co-treatment group demonstrated higher cell association 
relative to all other NP groups and higher levels of cell internalization relative to PEG NPs (Fig. 
115 
 
3). Interestingly, the MPG/PEG co-treatment group was the most efficacious in CaSki 
monolayers (Figs. 4-6, Table 2) but the least efficacious NP group in CaSki spheroids. These 
results substantiate previously observed trends that the bulk of NP uptake occurs along the tumor 
periphery (for hypovascularized lesions) and for tissue proximal to the vasculature (for 
vascularized tumors). When delivering therapeutic agents, it is important to consider that an 
adequate amount of NPs and associated therapeutic payload may not be internalized in cells 
distal from the vascular supply. These results are consistent with our previous 
experimental47,50,152 and computational modeling work47,48,51,59,60. 
While the effects of NP binding and penetration can be observed in tumor spheroids, the 
significance of NP penetration  is even more pronounced for treatment in hypoxic tumor 
conditions, where hypoxia is often associated with elevated levels of chemoresistance215. Our 
previous work50,151 has confirmed that spheroid growth impacts cell proliferation, apoptosis, and 
necrotic/hypoxic core formation, consistent with previous studies180. Moreover, these studies 
have noted that the outer layer (width ~100μm) is mostly proliferative, the middle layer hypoxic, 
and the inner core necrotic. These microstructural differences, in which the inner tumor layer is 
comprised of hypoxic cells, may contribute to decreased cell sensitivity to Dox, as hypoxic cells 
would be quiescent and thus avoid damage by the drug action during the cell cycle. Transient 
hypoxia has been shown to activate and upregulate genes encoding P-glycoprotein and 
dihydrofolate reductase, leading to resistance to drug substrates that are reliant on these 
molecules. Furthermore, tumor hypoxia has been shown to disrupt protein folding in the 
endoplasmic reticulum due to associated glucose deprivation219-221. This protein misfolding 
induces drug resistance to topoisomerase II-targeted drugs, such as Dox. In addition, Dox is 
known to react in the presence of oxygen and reduce to a superoxide which contributes to 
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cytotoxicity. Within the hypoxic regions of the tumor, these effects may be attenuated due to the 
decrease in free radical production. To overcome this increase in drug resistance, an effective 
delivery strategy would require NPs to adequately diffuse to the inner portion of the tumor and 
undergo subsequent cell internalization. As the results suggest, the ability of NPs to deliver an 
adequate therapeutic payload to inner portions of a tumor are highly dependent on tumor cell 
type and NP surface modification. This suggests that an effective drug delivery strategy may be 
possible by utilizing various NP surface modification ligands if the disease cell origin is known.  
The study presented here utilizes both single and co-treatment surface-modified NP delivery 
strategies to assess the efficacy of the chemotherapeutic Dox against hypovascularized cervical 
tumors of different disease origins. The results highlight the dependency of therapeutic efficacy 
on tumor cell type and the associated microenvironment. This offers the possibility to tailor the 
NP-mediated delivery strategy to maximize therapeutic efficacy based on patient-specific tumor 
tissue characteristics.  
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V. CONCLUSIONS  
We have presented single and dual NP delivery strategies, that utilize NPs modified with stealth 
and/or cell penetration ligands, to target hypo-vascularized tumor tissue. The results of these 
studies suggest the potential benefit that combination treatment, e.g., in which PEG NPs are used 
to achieve penetration into tissue distal from vasculature, while MPG NPs target proliferative 
regions close to blood vessels, may have in cervical cancer therapy.  Interestingly, while hybrid 
MPG/PEG NPs had similarly high uptake as MPG after 24 hr in tumor spheroids, lower uptake 
and penetration depth was observed, relative to either MPG or PEG NPs alone. In this case, 
internalization and diffusion may be competitive, thus inhibiting NP uptake and transport. These 
results highlight the well-known need to balance NP properties to achieve both adequate 
internalization and penetration through the tumor microenvironment. 
 
In contrast with utilizing NPs that are co-modified with stealth and cell penetrating ligands, 
subsequent results suggest that a co-treatment strategy may provide the greatest intratumoral 
penetration across a variety of cervical cancer disease/cell origins. For smaller, more regularly-
shaped tumor tissue, all surface-modified groups had similar distribution trends, relative to 
unmodified NPs. Moreover, for both smaller regularly- and larger irregularly-shaped tumors, if 
MPG/PEG NPs are administered at the same concentration as the modified NPs alone, the co-
treatment has the potential to offer an increase in NP penetration and distribution in all cell and 
tumor types. This provides hope that a NP co-treatment strategy may overcome the obstacles 
associated with NP tumor penetration and may influence the design of delivery platforms for 
cancer therapy, especially since tumors are expected to present both regularly- and irregularly-
shaped tissue regions.  
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Subsequent therapeutic efficacy studies highlight the importance of understanding the underlying 
cancer origin when treating cervical cancer. The work presented here suggests that for an 
adequate amount of drug payload to be achieved intratumorally, the NP drug delivery platform 
would be required to diffuse throughout the tumor and undergo subsequent cell internalization. 
These results underscore the dependency of NP tumor diffusion and cytotoxicity on cell and 
tumor type. As observed from this work, utilization of surface-modifications have the potential 
to increase NP transport throughout the tumor interstitium and improve cell internalization. Thus, 
this strategy offers a powerful drug delivery platform if disease origin is known. Long-term, the 
knowledge gained from these studies may offer guidance regarding the most efficacious 
strategies to treat tumors of varying cervical cancer origin and stages of tumor progression.  
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